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Abstract: The transition from normal glucose tolerance to impaired glucose tolerance and finally type 2
diabetes mellitus (DM) is driven by the cumulative loss of pancreatic beta-cell function and mass in the
background of peripheral insulin resistance. Inflammatory cytokines, e.g. interleukin (IL)-1beta, which
are elevated in inflammatory conditions of patients with metabolic diseases, induce beta-cell apoptosis.
A protective effect of high density lipoprotein (HDL) on pancreatic beta-cells against high glucose- and
IL-1beta-induced apoptosis was described previously. Thus, the goal of this project was to elucidate the
mechanism underlying the protective effects of HDL and its components in beta-cells.
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The transition from normal glucose tolerance to impaired glucose tolerance and finally type 2 
diabetes mellitus (DM) is driven by the cumulative loss of pancreatic -cell function and mass 
in the background of peripheral insulin resistance. Inflammatory cytokines, e.g. interleukin 
(IL)-1, which are elevated in inflammatory conditions of patients with metabolic diseases, 
induce -cell apoptosis. A protective effect of high density lipoprotein (HDL) on pancreatic  
-cells against high glucose- and IL-1-induced apoptosis was described previously. Thus, the 
goal of this project was to elucidate the mechanism underlying the protective effects of HDL 
and its components in -cells.  
We investigated IL-1-induced apoptosis in INS-1E cells, a rat -cell line, in the presence or 
absence of HDL and several of its components. The anti-apoptotic effect of HDL and the HDL 
protein moiety was specific and dose-dependent. However, an anti-apoptotic effect was not 
found for neither purified apolipoprotein (apo) A1, nor the HDL lipid moiety, nor spingosine-
1-phosphate. ApoC1 was identified as anti-apoptotic protein in HDL by mass spectrometry. 
Our experiments with HDL from apoC1-deficient and apoC1-transgene mice were ambiguous. 
Obviously, the protective effects of human and murine HDL on INS-1E cells were not easily 
comparable. A first study with human HDL from patients with metabolic diseases – who have 
decreased apoC1 levels in general – revealed a correlation between the apoC1 content of HDL 
and its anti-apoptotic potential irrespective of the glycemic state of the patient. However, 
there was no correlation between the apoC1 content of HDL and incident type 2 DM in a 
longitudinal study.  
A gene array analysis revealed a massive effect of IL-1 on gene transcription in INS-1E cells. 
The relatively small attenuation by HDL on IL-1-induced changes in gene expression was 
located in genes related to the unfolded protein response among others. Our results and 
results from other laboratories confirmed a protective role for HDL against endoplasmic 
reticulum (ER) stress. These protective effects were not mediated by apoC1, however.  
Unfortunately, additional experiments on the anti-apoptotic effect of apoC1 were impeded by 
major problems with our apoptosis model. 
Concluding experiments on the protective effects of HDL from type 1 and type 2 diabetic 
patients against ER-stress-induced apoptosis were performed with thapsigargin (ThG)-
stimulated apoptosis in INS-1E cells. Several adverse effects of metabolic diseases on the 
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protective properties of HDL were reported previously. Therefore, comprehensive 
experiments were done in endothelial cells and macrophages to check whether HDL from type 
1 and type 2 DM patients share dysfunctions, and whether the different functionalities of HDL 
correlate with each other. Unfortunately, the HDL samples from the different patient groups 
did not differ by their abilities to protect pancreatic -cells from ThG-induced apoptosis. In the 
comprehensive experiments no significant differences were detected neither with endothelial 
cells (i.e. measurements of the stimulated nitride oxide production, adhesion molecule 
expression, and inhibition of starvation-induced apoptosis), nor macrophages (i.e. cholesterol 
efflux measurements). With regard to the relatively high analytical variation of the bioassays 
and the rather small sample number, our study may have not been powered enough to find 
any significant differences between the control subjects and the patient groups. 
In conclusion, the ability of HDL to protect INS-1E cells from IL-1- and ThG-/ER-stress-induced 
apoptosis seems to rely on different structural determinants and mechanisms. However, our 
in vitro findings on the anti-apoptotic activities of apoC1 in HDL and could not be translated 




Der zunehmende Verlust von Funktion und Anzahl der pankreatischen -Zellen im Kontext der 
peripheren Insulinresistenz führt zum Übergang von normaler zu gestörter Glukosetoleranz 
und schliesslich zu manifestem Typ 2 Diabetes Mellitus (DM). Entzündungszustände, die bei 
Patienten mit metabolischen Erkrankungen häufig auftreten, führen zu zytokinvermittelter 
Apoptose der -Zellen. Vorgängig wurde bereits eine schützende Wirkung von High density 
Lipoprotein (HDL) auf pankreatische -Zellen gegen durch Glukose- und Interleukin (IL)-1-
induzierte Apoptose beschrieben. Das Ziel der hier vorgelegten Arbeit war nun die 
Entschlüsselung der Mechanismen des schützenden Effektes von HDL und seinen 
Bestandteilen auf -Zellen.  
Wir untersuchten die IL-1-induzierte Apoptose in INS-1E Zellen, einer -Zelllinie aus Ratten, 
mit und ohne HDL und verschiedenen HDL-Bestandteilen. Die anti-apoptotische Wirkung von 
HDL und seines Proteinanteils war spezifisch und dosisabhängig. Weder für das aufgereinigte 
Apolipoprotein (Apo) A1, noch für den Lipidanteil von HDL, noch für Sphingosin-1-Phosphat 
konnte jedoch ein solcher Effekt gezeigt werden. Mittels Massenspektrometrie wurde ApoC1 
als ein anti-apoptotisches Protein in HDL gefunden. Unsere Experimente mit HDL von ApoC1-
defizienten oder ApoC1-transgenen Mäusen waren leider uneindeutig. Die Wirkungen von 
menschlichem und murinem HDL liessen sich nicht direkt vergleichen.  
Eine erste Studie mit humanem HDL von Patienten mit metabolischen Erkrankungen, welche 
üblicherweise tiefere ApoC1-Spiegel haben, zeigte eine Korrelation zwischen dem ApoC1-
Spiegel und der anti-apoptotischen Wirkung des zugehörigen HDLs – ungeachtet des 
Nüchternen-Blutzuckers. Es fand sich jedoch keine Beziehung zwischen dem ApoC1-Spiegel 
des HDLs und Neuerkrankungen an Typ 2 DM in unserer prospektiven Studie.  
Eine Genexpressionsanalyse zeigte deutliche Veränderungen im Transkriptom von INS-1E 
Zellen nach IL-1-Exposition. Die Abschwächungen dieser Veränderungen durch HDL waren 
relativ klein und wurden unter anderem in der Unfolded Protein Response angezeigt. Unsere 
weiteren Resultate wie auch Resultate von anderen bestätigten eine schützende Wirkung von 
HDL gegen Stress im Endoplasmatischen Retikulum (ER) in -Zellen. Diese Wirkung wurde 
jedoch nicht von ApoC1 ausgeübt. Weiterführende Experimente zur anti-apoptotischen 
Wirkung von ApoC1 wurden unglücklicherweise durch schwerwiegende Probleme mit dem 
bisherigen Apoptosemodell verhindert.  
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Abschliessende Experimente zur schützenden Wirkung von HDL von Patienten mit Typ 1 und 
Typ 2 DM wurden in INS-1E-Zellen mit durch den ER-Stressor Thapsigargin (ThG)-induzierter 
Apoptose durchgeführt. Verschiedene Verschlechterungen der schützenden HDL-Wirkungen 
auf Endothelzellen waren bereits beschrieben worden. Daher führten wir weitergehende 
Experimente in Endothelzellen und Makrophagen mit diesen HDL-Proben durch, um zu testen, 
ob HDL von Patienten mit Typ 1 und Typ 2 DM ähnliche Funktionsstörungen tragen und ob 
diese miteinander korrelieren. Leider fanden wir keine signifikanten Unterschiede zwischen 
diesen HDL-Proben und den Kontroll-HDLs in der schützenden Wirkung gegen ThG-induzierte 
Apoptose in -Zellen. Auch in den Experimenten mit Endothelzellen (Messungen der 
stimulierten Stickstoffmonoxidproduktion, der Expression von Adhäsionsmolekülen und 
Verhinderung von durch Aushungern induzierter Apoptose) und Makrophagen (Messungen 
des Cholesterineffluxes) zeigten sich keine Unterschiede. Angesichts der relativ grossen 
Variation der Daten aus den Bioassays und der eher kleinen Probandenzahl, war unsere Studie 
vermutlich unterpowert, um signifikante Unterschiede zwischen den Patienten- und 
Kontrollgruppen festzustellen. 
Zusammenfassend kann man sagen, dass die Fähigkeit von HDL, INS-1E-Zellen vor der durch 
IL-1- und ThG-/ER-Stress-induzierte Apoptose offenbar auf verschiedenen strukturellen 
Faktoren und Mechanismen beruht. Leider konnten wir unsere Resultate zu den anti-
apoptotischen Wirkungen von HDL und ApoC1 nicht in Biomarker umsetzen, welche uns 
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4.1. Diabetes Mellitus 
The term “diabetes mellitus” (DM) describes several diseases that all are characterized by 
chronically elevated blood glucose levels, i.e. hyperglycemia 1. Hyperglycemia can be caused 
by the lack of insulin, the absence of insulin action, or both. Acute symptoms of DM are 
frequent urination, increased thirst and hunger, and weight loss. However, macrovascular and 
microvascular complications, the clinical sequelae of chronical hyperglycemia, are severe.  
 
4.1.1. History of Diabetes Mellitus 
Before 1500 A.C., the ancient Egyptian physician Hesy-Ra was the first known in history to 
describe polyuria in disease 2. About 1000 A.C., the Indian physician Shushruta Samhita 
described the sweet taste of the urine along with polyuria. The ancient Greek physicians 
associated the disease with the kidneys. In the end of the second century A.D., the Greek 
physician Aretaeus applied the term “diabetes” (which means “siphon”) in his very detailed 
description of the symptoms and stages of the disease 3. Around 1000 A.D., the Persian 
physician Avicenna differentiated between “primary” and “secondary” diabetes, the former 
being found in children, the latter associated with obesity. In the 17th century, the English 
physician Th. Willis differentiated between diabetes insipidus and diabetes mellitus, and 
thereby coined the terms. In 1889, J. von Mering and O. Minkowski performed 
pancreatectomy experiments with dogs, and linked the pancreas to diabetes mellitus 4,5. Later, 
Minkonwski and colleagues used pancreatic extracts to cure diabetes mellitus after 
pancratectomy in dogs. In 1921, insulin was isolated as a pure substance by F.G. Banting, Ch.H. 
Best, J. MacLeod, and J. Collip 6. One year later, purified bovine insulin was successfully used 
to treat a diabetic boy. In 1923, Banting and MacLeod were awarded the Nobel Prize in 
Physiology or Medicine for this discovery. Best and Banting made the purification procedure 
publicly disposable free of charge. Thus, insulin was rapidly available for treatment of diabetes 
around the world. In 1936, H.P. Himsworth established the clear differentiation between an 
insulin-sensitive and insulin-insensitive form of diabetes mellitus 7. However, researchers did 
not realize that most mature diabetic patients suffered from insulin-resistant tissue rather 
than secretory defects in -cells before the technology to quantify human insulin in plasma 
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with a radioimmunoassay was established in 1960 8,9. Furthermore, the fact that obese, non-
diabetic individuals showed higher insulin levels in response to a glucose load than healthy 
men at comparable glucose levels during the test led to the concept of a prediabetic state 10. 
Additionally, young diabetic patients were found to have low to undetectable levels of insulin. 
Thus, the different pathogenesis of type 1 and type 2 diabetes mellitus was established. 
 
4.1.2. Blood Glucose Homeostasis  
In healthy individuals, blood glucose levels are tightly regulated by the hormones insulin and 
glucagon. Both are produced by endocrine cells of the islets of Langerhans within the 
pancreas: Insulin by the -cells, glucagon by the -cells. Blood glucose regulation is important 
because a minimal glucose level is required for proper brain function. On the other hand, 
permanently high glucose levels induce macro- and microvascular diseases, and damage 
nerves. Diseases associated with chronically elevated blood glucose levels include 
atherosclerosis, neuropathy, retinopathy, and nephropathy 1.  
Blood glucose rises physiologically in the postprandial state. Thus, glucose diffuses from the 
bloodstream into the -cells via facilitated diffusion (mediated by glucose transporter GLUT-
2) where it stimulates insulin release. Insulin lowers the blood glucose levels via signaling to 
target cells: Adipocytes and muscle cells incorporate glucose via the insulin-sensitive glucose 
transporter GLUT-4 11,12. Glucose is stored in the form of glycogen (glycogenesis) in 
hepatocytes and muscle cells. In adipocytes, glucose is converted to fatty acids, and stored as 
triglycerides. These processes are stimulated by insulin. Moreover, the catabolism of fatty 
acids and amino acids into glucose (gluconeogenesis), and the catabolism of glycogen stocks 
in the liver (glycogenolysis) are inhibited by insulin.  
Glucagon, the antagonist of insulin, raises blood glucose levels by the induction of 
glycogenolysis in hepatocytes.  
 
4.1.3. -Cell Mass and Function 
A healthy human adult has approximately 1 million islets of Langerhans scattered in his 
pancreas that contain 2000 to 3000 -cells each 13.-cell mass is determined by the individual 
genome, intrauterine and early-life environmental factors, and lifestyle. It can expand in 
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adults upon demand, such as pregnancy, overweight, and insulin resistance in metabolic 
syndrome 14–16. -cell mass was found to be increased by 50 to 90% in overweight and obese 
individuals 17. The proliferative capacity of rodent -cells seems to be much higher compared 
to human -cells 13. However, neogenesis could possibly provide additional -cells for -cell 
mass expansion 18. 
The main functions of -cells are insulin production and insulin secretion upon demand. 
Insulin is expressed as preproinsulin which undergoes massive procession to form active 
insulin. In the endoplasmic reticulum (ER), the signal peptide is cleaved off, and the three 
disulfide bridges are formed to stabilize the protein. The folded proinsulin is then transported 
to the trans Golgi network where it is packed into immature vesicles. During the maturation 
of the insulin vesicles, the C-peptide is cleaved from proinsulin. Thus, mature vesicles filled 
with fully processed insulin are in stand-by for release 19. For the elucidation of the primary 
structure of bovine insulin, F. Sanger received the Nobel Prize in Chemistry in 1958.  
In non-diabetic individuals, a pulsatile insulin secretion is present in the fasted state, though 
at low levels 20. Cytosolic Ca2+ levels, which have a pulsatile pattern itself, regulate this 
oscillation. At elevated blood glucose levels, glucose enters -cells via GLUT-2 21. In the cytosol, 
glucose is metabolized to glucose-6-phosphate which enters glycolysis in the mitochondria. 
The generated adenosine triphosphate (ATP) induces the closure of ATP-sensitive K+-channels, 
which in turn depolarizes the plasma membrane of the cell. Consequently, voltage-gated Ca2+-
channels open, and calcium ions enter the cell. The elevated Ca2+ concentration in the cytosol 
leads to the fusion of primed (“readily releasable”) insulin-filled vesicles to the plasma 
membrane, i.e. the first-phase insulin secretion. This first-phase insulin secretion happens 
three to five minutes after the rise in blood glucose, and lasts about ten minutes. The first-
phase insulin secretion mediates the switch from the fasted to the fed state, including the 
suppression of hepatic glycogenolysis and lipolysis in adipocytes 20. The second-phase insulin 
secretion is slower but more enduring. It requires insulin-filled vesicles to be transported to 
the cell membrane and priming. This process is promoted by incretins, i.e. gastro-intestinal 
hormones that are secreted in the postprandial state. 
To maintain insulin secretion, more insulin has to be produced, and new granules have to be 
prepared. Several transcription factors regulate the expression of the insulin gene. Among 
others, glucose and the resulting cyclic adenosine monophosphate (cAMP, which binds to the 
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transcription factor cAMP response element binding protein (CREB)) induce the expression of 
insulin 22.  
In addition to the above described expansion of -cell mass in response to an increased 
metabolic demand, -cells are able to upregulate insulin production by several fold 17. 
Nevertheless, insulin hypersecretion of -cells of non-diabetic, obese individuals still follows 
a physiologically pulsatile pattern with about 11 pulses per day 23. 
 
4.1.4. Type 1 and Type 2 Diabetes Mellitus 
The global report on diabetes 24 estimated that 422 million adults suffered from diabetes in 
2014, a pronounced rise compared to 108 million in 1980. Since then, the global prevalence 
(age-standardized) of diabetes augmented from 4.7% to 8.5% in the adult population. In 
Switzerland, the prevalence of diabetes in adults was estimated to be 5.6% for 2014 24. Since 
Western life-style with an abundance of high caloric food and a lack of physical exercise is 
spreading, it is expected that worldwide the cases of type 2 DM will increase to 693 million by 
2045 25.  
Both, type 1 and type 2 diabetes mellitus (DM) are characterized by chronically elevated blood 
glucose levels 1. In type 1 DM the cause for the hyperglycemia is the absence of sufficient  
-cells: In an autoimmune reaction, the immune system attacks the -cells and destroys most 
of them. The remaining -cells cannot produce an adequate amount of insulin to maintain 
normoglycemia: We observe an absolute insulin deficiency with decreased insulin production 
but normal insulin demand.  
In type 2 DM, which accounts for the majority of all DM cases, subjects have a pronounced 
insulin resistance in peripheral tissues 15. As long as the body compensates the increased 
insulin demand with increased insulin production and secretion, subjects maintain 
normoglycemia. Type 2 DM manifests when the insulin production fails to control blood 
glucose levels: We observe a relative insulin deficiency with a normal or decreased insulin 




4.1.5. Pathogenesis of Type 2 Diabetes Mellitus 
Long before the possible manifestation of type 2 diabetes, insulin resistance in hepatocytes, 
myocytes, adipocytes, and other cells is found as part of the metabolic syndrome 26. 
Furthermore, the metabolic syndrome is associated with obesity, ageing, and physical 
inactivity. In insulin resistance, glucose uptake into myocytes and adipocytes is reduced, and 
glycogen synthesis is decreased in hepatocytes 11. Thus, less glycogen is stored in muscle and 
liver cells, and lipogenesis is decreased in the adipose tissue. Moreover, gluconeogenesis and 
glycogenolysis in hepatocytes, as well as hydrolysis of triglycerides in adipocytes are not 
suppressed sufficiently in the insulin resistant state. This results in increased glucose and free 
fatty acid levels in the circulation. The latter further attenuates insulin sensitivity in peripheral 
tissues. In response to insulin resistance, insulin production is increased by upregulation of 
insulin synthesis and secretion, and/or expansion of -cell mass 15. Thus, most of insulin 
resistant individuals maintain normoglycemia for years or even the rest of their life. 
Hyperglycemia and type 2 DM develop once the -cells fail to produce and secrete sufficient 
insulin to meet the metabolic demand.  
Butler and colleagues analyzed the pancreatic tissue of 124 autopsies 27. Whereas the -cell 
mass of diabetic patients was in the range of healthy, lean individuals, -cell mass was up to 
50% higher in obese non-diabetic subjects. Subjects with type 2 DM thus had less -cell mass 
than their non-diabetic weight- and age-matched controls. The abundance of a marker for 
proliferation was low but did not differ between obese subjects with and obese subjects 
without type 2 DM. Conversely, apoptosis was tenfold elevated in the islets of obese subjects 
with type 2 DM compared to non-diabetic, obese subjects. This indicates that during the 
pathogenesis of type 2 DM there is a concomitant loss of (previously expanded) -cell mass. 
In accordance with this, a reduction in -cell mass of 24 to 65%, possibly depending on disease 
duration, has been reported by different studies 17. Mechanisms leading to -cell apoptosis 
are described in section 4.2.4 below. 
The remaining -cells exhibit impaired function. Compared to healthy individuals, the insulin 
secretion capacity was found to be decreased by 50 to 97% in type 2 DM patients 17. Insulin 
synthesis is decreased in -cells of diabetic patients. The transcription of the insulin gene is 
regulated by the interaction of ubiquitous and islet specific transcription factors which 
activate the insulin promoter 28. High glucose levels as well as the incretin GLP-1 (glucagon-
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like peptide-1) increase intracellular cyclic adenosine monophosphate (cAMP) concentration. 
cAMP induces PDX-1 (pancreatic and duodenal homeobox 1), an important transcription 
factor for insulin via PI3 (phosphatidylinositide 3) and MAPK (mitogen-activated protein 
kinase) pathways. These can be induced by external (acute) stimuli such as glucose, GLP-1, 
insulin, or palmitate. However, prolonged exposure to high glucose or palmitate 
concentration was found to reduce PDX-1 levels in -cells. Moreover, preproinsulin needs to 
undergo posttranslational modification before it is active: Cleavage of the signal peptide, 
formation of disulfide bridges, and protein folding happen in the ER 19. ER stress, which occurs 
as a consequence of chronic exposure to high glucose concentration or high free fatty acid 
levels, stalls the procession of the protein 29. Increased levels of free fatty acids, such as 
palmitate, are found in obese subjects before hyperglycemia occurs. Since palmitate alone 
elicits ER stress by hampering the transfer of proteins to the trans-Golgi network, it is possible 
that this fatty acid impedes the procession of preproinsulin. When ER stress persists, chronic 
ER stress can lead to apoptosis. Studies in transgenic mice and with mutated cholesterol 
efflux-related proteins in humans indicate that cholesterol homeostasis is crucial for proper 
-cell function. These studies are discussed below in section 4.3.5. 
Besides decreased insulin synthesis, the remaining -cells display a disturbed secretion 
pattern in type 2 DM. As mentioned above, insulin is secreted in a first and second peak when 
blood glucose rises in normoglycemic subjects. The first-phase insulin secretion is lost in type 
2 DM patients at the time of diagnosis 20. The second-phase insulin secretion is usually delayed 
and reduced. Reduction in the first-phase insulin secretion is often found before the 
manifestation of the disease, i.e. in individuals with impaired glucose tolerance, as well as in 
first-degree relatives of type 2 DM patients. Subjects without first-phase insulin secretion are 
therefore considered at high risk for developing type 2 DM.  
The exact causes – as well as their interactions – that lead to -cell dysfunction and apoptosis 
are still to be determined. Possible pathogenic mechanisms include mitochondrial 
dysfunction, oxidative stress, ER stress, glucolipotoxicity, and amyloid deposition 15,30. 
Moreover, most of these mechanisms are related to tissue inflammation and influence both, 
insulin resistance and -cell failure. Clinical studies in which different inflammatory pathways 






4.2.1. Different Cell Death Routines 
Several modalities of cell death are differentiated into apoptosis, necrosis, autophagy, and 
other, more specialized forms. Historically, the cell death categories were defined by 
morphological changes occurring in the dying cell. Apoptosis was defined by cell shrinkage, 
chromatin condensation, nuclear fragmentation, extracellular exposure of 
phosphatidylserine, membrane blebbing, and engulfment of cell components into “apoptotic 
bodies” 31. The remainders of the apoptotic cell are phagocytosed by macrophages or taken 
up by neighboring cells. In contrast to this regulated cell death, necrosis was defined as 
uncontrolled cell death in response to harsh cell or tissue damage. Here, the cells swell, cell 
membranes rupture, and cell components are released that cause a local inflammatory 
response.  
Nowadays, several biochemical parameters are measured to determine and quantify 
apoptosis as well as other forms of cell death 32. Since there is an overlap of features of 
different cell death pathways, several biochemical parameters should be measured in order 
to define the cell death mechanism. Moreover, biochemical actions related to cell death can 
occur at a sublethal level (i.e. at a reversible state) or be caused by a process other than cell 
death (e.g. proliferation). 
  
4.2.2. Extrinsic Apoptosis 
Extrinsic apoptosis is a cell death pathway in which an extracellular stress signal (e.g. FAS-
ligand, tumor necrosis factor (TNF)) induces caspase-dependent apoptosis via specific 
transmembrane receptors (e.g. FAS receptor, TNF receptor) 32. Specific cytosolic proteins and 
procaspases (e.g. procaspase 8, procaspase 10) are recruited to the intracellular death 
domain, where these (initiator) caspases are cleaved and thereby activated. Activated caspase 
8 (or 10) cleaves and activates effector caspases (e.g. caspase 3, 6, and 7) directly in some cell 
types. In other cells, such as pancreatic -cells, active caspase 8 cleaves BID (Bcl-2 homology 
3 interacting-domain death agonist), a pro-apoptotic member of the Bcl-2 (B-cell lymphoma 
2) family proteins which initiates mitochondrial outer membrane permeabilization (MOMP). 
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MOMP induces the formation of the apoptosome (described below) which activates 
procaspase 9 by cleavage. Thus, caspase 9 activates the effector caspases.  
 
4.2.3. Intrinsic Apoptosis 
Intrinsic apoptosis occurs via a caspase-dependent or -independent pathway 32. The elicitor of 
intrinsic apoptosis is pronounced intracellular stress which possibly originates from DNA 
damage, oxidative stress, cytosolic Ca2+ overload, and/or accumulation of unfolded proteins 
in the endoplasmic reticulum (ER). Such stress signals unbalance the homeostasis of pro- and 
anti-apoptotic signals at the mitochondrial membrane. In healthy cells, anti-apoptotic Bcl-2 
family proteins such as Bcl-2 (B-cell lymphoma-2), Bcl-xL (Bcl-extra large), and Mcl-1 (myeloid 
cell leukemia 1) maintain the mitochondrial transmembrane potential as they prevent pro-
apoptotic BCL-2 family proteins such as Bak (Bcl-2 homologous antagonist/killer), Bax (Bcl-2-
associated X protein), Bad (Bcl-2-associated death promoter), Bid (BH3 interacting-domain 
death agonist), Bim (Bcl-2-like protein 11), and Puma (p53 upregulated modulator of 
apoptosis) from the induction of pore formation in the outer mitochondrial membrane by 
physical interaction 33. Once the mitochondrial outer membrane is permeable (MOMP), 
proteins residing in the mitochondrial intermembrane space (IMS) are released into the 
cytosol. These IMS-proteins have different functions in the intrinsic apoptotic pathway: 
cytochrome C becomes part of the apoptosome, apoptosis-inducing factor (AIF) and 
endonuclease G (endoG) digest DNA in the nucleus, HTRA2 (high-temperature requirement 
serine peptidase 2) cleaves actin filaments, DIABLO/SMAC (direct IAP (inhibitor of apoptosis 
protein)-binding protein with low PI / second mitochondria-derived activator of caspases) and 
HTRA2 inhibit anti-apoptotic factors. Besides the release of IMS-proteins, lethal consequences 
of MOMP are the dissipation of the mitochondrial membrane potential with the resulting 
cessation of mitochondrial ATP synthesis, and the inhibition of the respiratory chain, which is 
accompanied by overproduction of reactive oxygen species (ROS). The apoptosome, 
consisting of cytochrome C, APAF-1 (apoptotic protease activating factor 1), and dATP 
(deoxyadenosine triphosphate), activates caspase 9 which in turn cleaves procaspase 3 into 
active caspase 3 that commonly operates apoptosis.  
The caspase-independent intrinsic apoptosis is executed directly by enzymes from the IMS 
(i.e. HTRA2, endoG and AIF), which digest cell components such as DNA and the cytoskeleton, 
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or is induced by the cessation of ATP, excess ROS production, or the inhibition of the 
respiratory chain.   
 
4.2.4. -Cell Apoptosis 
In both, type 1 and type 2 DM, -cell apoptosis is a major pathogenic event 33,34. In type 2 DM, 
death receptor-mediated (extrinsic) as well as intrinsic apoptosis are potentially relevant for 
apoptosis 35.  
Intrinsic apoptosis in pancreatic -cells has been described as a reaction to ER stress 36 (Fig 
4.1). High glucose and/or elevated free fatty acid levels stimulate insulin secretion if they are 
present for a short time – if theses stimuli persist, they induce ER stress. Constantly high 
glucose levels were found to cause a maladjustment of the pro- and anti-apoptotic BCL-2 
family proteins, which induces MOMP and subsequent apoptosis 37. Whereas short term 
glucose exposure induces the expression of chaperones which sustain the elevated demand 
for insulin, long term exposure to high glucose was found to cause ER stress-induced  
apoptosis 38. CHOP (C/EBP homologous protein) is an ER stress induced transcription factor 
downstream of PERK (protein kinase R-like endoplasmic reticulum kinase) and ATF6 
(Activating transcription factor 6). CHOP downregulates BCL-2 and upregulates DP5 (death 
protein 5) as well as Bim (Bcl-2 interacting mediator of cell death). The consequences of ER 
stress-induced CHOP expression are therefore likely to induce apoptosis via MOMP. The fatty 
acid palmitate was shown to induce factors of the unfolded protein response (UPR; i.e. PERK, 
ATF6, and IRE (inositol-requiring enzyme) 1 signaling) and apoptosis in INS-1E cells, rat  
-cells, and human islets 39. Potentiation of this effect with high glucose was minor, however. 
Subsequently, palmitate-induced factors of the UPR were found to be associated with the up- 
and downregulation of pro- and anti-apoptotic BCL-2 family proteins in a manner that favors 
apoptosis 40.  
As mentioned above, metabolic syndrome and obesity often precede type 2 DM. Adipose 
tissue secretes inflammatory factors such as interleukin (IL)-1 and tumor necrosis factor 
(TNF) 30. Since the IL-1 receptor is highly expressed in -cells, these cells are potentially very 
susceptible to IL-1. At elevated glucose levels, -cells produce and release IL-1 41. 
Furthermore, free fatty acids and their metabolites stimulate IL-1 release from -cells 30. 
Macrophages are attracted to pancreatic islets in the diabetic milieu 42. NLRP3 (NLR family 
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pyrin domain containing 3) which is highly expressed in macrophages could further contribute 
to the IL-1 production in pancreatic islets 35. The fact that -cells seem to possess an internal 
protection system against IL-1, i.e. the local expression of the IL-1 receptor antagonist, 
emphasizes the vulnerability of -cells to inflammation 43.  
 
 
Figure 4.1: Schematic representation of the possible cross talks between UPR and pro-
inflammatory pathways in pancreatic -cells under ER stress 36.  
Pro-inflammatory cytokines (IL1, TNF, and IFN among others), lipids (free fatty acids), human islet 
amyloid polypeptides (hIAPP) aggregates, and SERCA2 Ca2+ pump blockers induce ER stress by diverse 
mechanisms such as NO formation, ROS production, and ER calcium depletion leading to UPR 
activation in pancreatic -cells. ER stress induced phosphorylation of PERK, and the activation of 
ATF6 and IRE1α induce signaling cascades, partially via JNK and NF-B, which increase the expression 
of chaperones, endoplasmic-reticulum-associated protein degradation (ERAD) components, CHOP, 
and several pro-inflammatory genes. This ER stress-mediated inflammatory state contributes to the 
maintenance of ER stress and probably leads to -cell demise. 
 
In -cells, IL-1 and TNF (a ligand which induces extrinsic apoptosis via TNF receptor) both 
activate nuclear factor kappa B (NF-B) which can promote cell survival or mediate cell death 
via increased nitric oxide (NO) production 44,45. The cytokines IL-1 and interferon (IFN)- were 
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found to induce NO production via NF-B/iNOS (inducible NO synthase) in -cells 46. The 
elevated NO levels disturb the Ca2+ homeostasis of the ER by down regulation of SERCA 
(sarco/endoplasmic reticulum Ca2+-ATPase), a Ca2+ pump, and thus induce ER stress and 
apoptosis. Chan and colleges suggested the c-Jun N-terminal kinase (JNK) as a key regulator in 
the transition from the adaptive UPR which resolves ER stress to the destructive UPR which 
initiates apoptosis 47. They described that the imbalance of CHOP and XBP1 (X-box binding 
protein 1), which occurs in ER stress conditions as a response to cytokine or palmitate 
exposure, favors the apoptotic over the adaptive UPR. Moreover, they postulated that ER 
stress as an early event in the pathogenesis of diabetes precedes oxidative stress and 
inflammation. The important role of JNK and cytokine-induced ER stress in -cell apoptosis of 
mice, rats, and humans was also described by Brozzi and colleges 48. Additionally, they found 
differences between species: Whereas NO inhibition prevented cytokine-induced apoptosis in 
rat -cells, murine and human -cells were not protected from ER stress and apoptosis 
induced by cytokines.  
Besides a plausible role for cytokine-induced ER stress in -cell apoptosis, direct effects of the 
inflammatory cytokines IL-1, IFN- and/or TNF-on the mitochondrial apoptotic pathways 
have been described 33. Inflammatory cytokines may shift the balance of pro- and anti-
inflammatory members of the Bcl-2 family of proteins by modulating the activity and 
expression of these proteins. This triggers the mitochondrial outer membrane permeability 
(MOMP, described in section 4.2.3.).  
Another factor described to induce apoptosis is the deposition of human islet amyloid poly-
peptide (hIAPP) in -cells. The amount of these depositions was found to correlate with -cell 
apoptosis and decreased -cell area in human pancreatic samples 49. The treatment of islets 
isolated from transgenic mice overexpressing human IAPP with elevated glucose conditions 
resulted in the upregulation of genes belonging to the extrinsic pathway (Fas ligand and Fas-
associated protein with death domain (FADD)) and the intrinsic pathway (Bim) 50. In both 
apoptotic pathways, hIAPP activated JNK signaling and caspase 3 cleavage. Moreover, islet 
macrophages may produce IL-1 in response to hIAPP-deposits which is harmful for the islet 
-cells 51. A more recent study found that besides the upregulation of IL-1 in human islets 
concomitant with -cell dysfunction and apoptosis, the natural IL-1 antagonist, IL-1 receptor 
antagonist (IL-1RA) was downregulated by amyloid formation 52.  
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Whereas FAS ligand is not expressed in -cells at normal circumstances, high glucose 
concentrations were found to induce FAS ligand expression in pancreatic -cells 53. Thus, the 
constitutional expression of FAS ligand could induce extrinsic apoptosis. 
Several compounds that influence inflammatory cytokines and possibly -cell apoptosis have 
been tested in clinical trials which are described in the following section.  
 
4.2.5. Clinical Studies on Inflammation in Type 2 Diabetes Mellitus 
Methods to monitor -cell apoptosis in living humans are not available to date. Therefore, 
clinical studies cannot provide detailed information about anti-apoptotic effects of the tested 
compounds 33. Nevertheless, indirect evidence points to an interference of inflammatory 
pathway modulators with -cell apoptosis. Blocking systemic inflammation by the use of 
salicylates was demonstrated to be an effective strategy to improve hyperglycemia in type 2 
diabetes patients 30,54,55. The relevance of TNF, macrophages, and IL-1 in the development 
of type 2 DM and possibly in -cell apoptosis was demonstrated in several studies in which 
the respective targets were inhibited or antagonized 56.  
Treatment with a TNF inhibitor reduced HbA1c levels in patients with newly diagnosed type 
1 DM as well as their daily insulin dose compared to the placebo-treated patients in a pilot 
study 57. In obese individuals, albeit without type 2 DM, 6 months TNF inhibition treatment 
reduced fasting glucose levels 58.   
A small study found modest glycemic improvements, possibly due to improved -cell function, 
in type 2 DM patients treated with C-C chemokine receptor-2 (CCR2) antagonist, which 
impedes macrophage recruitment 59.  
Administration of an IL-1 receptor antagonist improved glycemia durably in type 2 DM 
patients 60,61. This effect was confirmed in several smaller studies 33,62. In a crossover study, 
treatment with an IL-1 receptor antagonist improved first-phase insulin secretion and the 
insulinogenic index in subjects with impaired glucose tolerance 63. The subsequent hypothesis 
that IL-1 antagonism could prevent incident type 2 DM was addressed within the CANTOS 
(Canakinumab Anti-inflammatory Thrombosis Outcomes Study) trial which included more 
than 10’000 individuals with prior myocardial infarction and elevated high-sensitivity C-
reactive protein (hs-CRP) 64. Treatment with three different doses of the monoclonal IL-1 
antibody resulted in significant reductions of cardiovascular events compared to placebo. 
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Despite remarkable reductions in markers of subclinical inflammation (i.e. hs-CRP and 
interleukin 6) however, the rates of incident diabetes were not significantly different between 
the treatment groups among the almost 5000 persons with pre-diabetes (i.e. HbA1c of 5.7 to 
<6.5% and/or fasting plasma glucose of 5.6-6.9 mmol/L). There was but a trend towards lesser 
cases of incident type 2 DM with anti-IL-1 treatment in the first three years of the study 
which was inverted in participants after four years of treatment. Study participants with pre-
diabetes profited from IL-1 neutralization in terms of reduced HbA1c levels in the first six to 
nine months of the study. Moreover, a reduction in HbA1c was observed in normoglycemic 
and diabetic participants at trial entry. Then, the effect on HbA1c was attenuated in all 
participants and after 48 months, no statistically significant differences in HbA1c levels were 
recorded between the treatment groups irrespective of their glycemic status. Possibly, the 
attenuation of the differences in HbA1c originated from lifestyle interventions or changes in 
other anti-diabetic therapies which were allowed by the study protocol. The absence of an 
effect of the IL-1 inhibitor on incident type 2 DM might arise from the inclusion criteria (prior 
myocardial infarction and elevated hs-CRP) of the study which in turn limit the informative 
value of the results on the general population. 
Thus, further studies on inflammatory mediators are required to clarify the role of 







Cholesterol is a vital component of the cell membranes of vertebrate cells 65. As such, it 
regulates membrane fluidity and permeability. Regions with high cholesterol content, termed 
lipid rafts, are characterized by low fluidity. Lipid rafts are often involved in signaling 
processes, as many receptors reside within these parts of the membrane. Moreover, 
cholesterol is the precursor for bile acids, steroid hormones, and vitamin D.  
In humans, about 30% of the required cholesterol is food-derived, the remainder is 
synthesized de novo by the cells of the body. Cholesterol synthesis is tightly regulated. 
Changes in dietary cholesterol are physiologically compensated by up- or downregulated de 
novo cholesterol synthesis. All nucleated cells are capable of cholesterol synthesis by the 
mevalonate pathway, in which the rate-limiting step is catalyzed by hydroxymethylglutaryl 
CoA reductase (HMG-CoAR). The sterol regulatory element binding protein (SREBP) 
upregulates cholesterol synthesis by the upregulation of HMG-CoAR.  
Cholesterol is a lipid and thus not soluble in the aqueous lymph and blood stream. 
Nevertheless, it needs to be transported from the sites of uptake or de novo synthesis to 
target cells, including steroidogenic cells. This is termed forward lipid transport. In the reverse 
lipid transport, excess cholesterol from peripheral tissue is transported to the liver for 
excretion. For both directions of transport, cholesterol is packed into lipoproteins.   
 
4.3.2. Lipoprotein Structure and Metabolism 
The main function of lipoproteins is the transport of lipids in the blood stream and lymph 66. 
Amphipathic apolipoproteins, phospholipids (PL), and free cholesterol (FC) emulsify different 
hydrophobic lipids (mainly triglycerides (TG) and cholesterol esters (CE)) in the hydrophobic 
core. Lipoproteins have a similar general structure. However, coinciding with their 
composition, they have specific transport tasks.  
Lipoproteins are categorized according to their density (Tab. 4.1) with high-density lipoprotein 
(HDL) having the highest density and smallest diameter, and chylomicrons at the other edge 





 Density [g/ml] Size Lipids  Apolipoproteins 
Chylomicron <0.940 100-600 nm TG, PL, CE, FC B48, A1, A4, C1, C2, C3, E 
VLDL 0.940-1.006 60 nm approx. TG, PL, CE, FC B100, C1, C2, C3, E  
LDL 1.006-1.063 25 nm approx. CE, PL, FC, TG B100 
HDL 1.063-1.210 7-12 nm PL, CE, FC, TG A1, A2, A4, A5, C1, C2, C3, 
C4, D, E, F, H, J, L1, M 
Tab. 4.1: Lipoprotein characteristics and composition 67,68 
 
Chylomicrons originate from the enterocytes after a meal 66,69. Their main apolipoprotein 
(apo) is apoB48, a truncated form of apoB100 which is produced by the intestine. Chylomicrons 
transport dietary lipids initially in the lymph, and enter the systemic bloodstream via the 
thoracic duct. There, they deliver their lipids either to adipose tissue for energy storage, or to 
striated muscle for combustion. The lipoprotein lipase hydrolyses the TG in the chylomicrons 
on thin capillaries of adipose tissue and striated muscle cells. Alternatively, chylomicrons can 
transfer lipids to HDL in circulation. The lipid-depleted chylomicron remnants are internalized 
by hepatocytes, where the remaining cholesterol is used for bile acid synthesis, integrated in 
other lipoproteins, or excreted via feces 66,69.  
Very low density lipoproteins (VLDL) have a similar role in forward lipid transport as 
chylomicrons. However, they are synthesized in hepatocytes, and export endogenously 
synthesized or recycled TG and CE from the liver to peripheral tissue. VLDL contain the full-
length apolipoprotein apoB100 as its main apolipoprotein. After the transfer of TG and several 
apolipoproteins other than apolipoprotein B100 to HDL, VLDL remnants are taken up by the 
liver, or further remodeled into low density lipoprotein (LDL) in circulation 66.  
LDL is the product of VLDL remodeling in circulation. It contains apoB100 as the only 
apolipoprotein. The main function of LDL in the human body is to deliver CE to peripheral 
tissue and the liver 68. CE is imported by LDL receptor-mediated endocytosis of LDL into target 
cells 70. An increase in cellular cholesterol causes the downregulation of the LDL receptor via 
the transcription factor SREBP.  
Depending on its composition, HDL occurs as spherical or discoidal particle 68,71. HDL is 
synthesized in the liver and intestine, where apoA1 (HDL’s main apolipoprotein) is produced 
and subsequently lipidated with phosphatidyl choline (PC) and cholesterol by ABC (ATP-
binding cassette transporter) A1  (Fig. 4.2) 72. Although ABCA1 is expressed ubiquitously in the 
body, lipidation of apoA1 by hepatocytes and enterocytes directly after secretion accounts for 
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the majority of HDL formation. PL, mostly PC, and other proteins are added to HDL in 
circulation. The enzyme lecithin-cholesterol acyltransferase (LCAT) mediates the conversion 
of free cholesterol (FC) into cholesterol ester (CE), and thereby rapidly induces the conversion 
of discoidal HDL precursors into spherical particles 73. Cholesterol ester transfer protein (CETP) 
activity introduces TG from VLDL, LDL, and chylomicrons to HDL in exchange for CE. HDL 
receives small exchangeable apolipoproteins from other lipoproteins; cholesterol and PC from 
cells mediated by the ABCA1, the ABC transporter G1 (ABCG1) or scavenger receptor class B 
type I (SR-BI). The assembly of PL from TG-rich lipoproteins is mediated by phospholipid 
transfer protein (PLTP). HDL is an important acceptor for excess cholesterol from extrahepatic 
tissues which are not able to catabolize cholesterol. HDL transports the cholesterol to the liver 
for excretion with the bile (i.e. reverse cholesterol transport) 66,74.  
 
 
Figure 4.2: Lipoprotein metabolism and generation of HDL75.  
Abbreviations are described in the text, apoA-I corresponds to apoA1  
 
 
4.3.3. HDL Composition 
Lipids 
Similarly to other lipoproteins, HDL carries phospholipids (PL, 37-49 mol % of total lipids of 
HDL) and unesterified/free cholesterol (FC, 9-14% mol % of total lipids of HDL) on the surface 
71,76. The amount of PL per particle is related to the surface of the particle. The hydrophobic 
28 
 
core of HDL consists of cholesterol ester (CE, 35-37 mol % of total lipids of HDL) and 
triglycerides (TG, approximately 3 mol % of total lipids of HDL). The amount of FC is rather low 
because the enzyme lecithin-cholesteryl-acyl transferase (LCAT), which converts FC to CE, 
resides on HDL. HDL also contains several sphingolipids at lower abundance, including 
sphingosine-1-phosphate, a bioactive lipid. Moreover, oxysterols, steroid hormones, and lipid-
soluble vitamins (A and E) are transported by HDL. In total, more than 200 lipid species have 
been identified in HDL 67. 
 
Proteins 
Around 100 different proteins are regularly identified in HDL 67,71,77,78. By weight, 70% of HDL 
proteins consist of apoA1, 20% of apoA2, and the remaining 10% are other apolipoproteins as 
well as enzymes and other proteins. Interestingly, not every HDL particle contains all proteins 
found in the whole HDL fraction 79. All of the apolipoproteins found on HDL (Tab. 4.1) are 
relatively small and exchangeable between lipoproteins 74,78. 
Two to five molecules of apoA1 molecules are usually found per HDL particle 67. Lipid-poor or 
lipid-free apoA1 is rapidly cleared from the circulation by the kidneys 74. The second most 
abundant apolipoprotein on HDL, apoA2, is predominantly produced in hepatocytes 71. It has 
a high affinity for lipids 72. About half of all HDL particles contain apoA2 71. ApoA4 is mainly 
synthesized in the intestine from where it is released as chylomicron component. In the blood 
circuit it is transferred to HDL 72. ApoE is predominately synthesized in the liver and integrated 
into VLDL particles. Upon hydrolysis of VLDL, apoE is incorporated by HDL. The apolipoproteins 
apoC1, apoC2, apoC3, apoC4, apoD, apoF, apoH, apoJ, apoL1, and apoM, are found on HDL 
less abundantly. Nevertheless, these apolipoproteins do have specific functions. They activate 
or inhibit enzymes involved in HDL metabolism 68,71: LCAT is activated by apoA1, apoA4, apoE, 
apoC1; LPL is activated by apoA5 and apoC2, and inhibited by apoC1 and apoC3 80; hepatic 
lipase is activated by apoA1 and apoE 72, but inhibited by apoC1, apoC3 and apoA2; CETP is 
inhibited by apoC1 81 and apoF. In addition to its functions as activator or inhibitor of specific 
enzymes, apoC1 was found to inhibit the SR-BI-mediated CE uptake in hepatocytes 82. Thus, 
apoC1 increases HDL cholesterol (HDL-C) levels. Since VLDL levels are increased by apoC1 as 
well, a therapeutic application of apoC1 seems limited 82. Moreover, apolipoproteins mediate 
the interaction of lipoproteins with specific receptors, e.g. ABCA1 interacts with apoA1.  
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Besides apolipoproteins, lipoprotein remodeling proteins are carried by HDL, e.g. LCAT, PLTP, 
and CETP 67,71,78. Furthermore, antioxidant enzymes like paraoxonases (PON1 and PON3) or 
myeloperoxidase, and proteins of the acute phase response, complement regulation, 
proteinase inhibitors, and proteins involved in the immune response and homeostasis have 
been identified in HDL 71.  
 
4.3.4. Cellular HDL-Interacting Proteins 
After the secretion of apoA1 from the liver and intestine, apoA1 interacts with the ABC 
transporter A1 (ABCA1) on hepatocytes and enterocytes. At this rate-limiting step in HDL 
biogenesis, apoA1 acquires cholesterol and phospholipids 73,83. Whereas mature HDL is not 
able to bind to ABCA1, poorly lipidated apoA1, newly synthesized or as a result of HDL 
recycling, induces lipid efflux via ABCA1. For this efflux, lipids are sequestered in the 
extracellular domains of ABCA1 in an ATP-dependent manner 84. Lipid-laden ABCA1 
monomers dimerize and transfer phospholipids and cholesterol to apoA1. Moreover, the 
interaction of apoA1 with ABCA1 protects ABCA1 from degradation and induces intracellular 
signaling pathways, such as protein kinases A and C, and Janus kinase 2 85. ABC transporter G1 
(ABCG1) plays a role in lipid homeostasis of cell and organelle membranes. It mediates 
cholesterol efflux to HDL. However, this process is not rate-limiting in the formation of  
HDL 73,83. Both, ABCA1 and ABCG1, are regulated on transcriptional and posttranscriptional 
levels. Excess cholesterol, notably after oxidation to oxysterols, activates the liver X receptor 
which upregulates the expression of ABCA1 and ABCG1, thus promoting cholesterol efflux 74. 
ABCG1 and ABCA1 were shown to balance the cholesterol content of lipid rafts which is crucial 
for signaling processes including proliferation and inflammation 85. 
Savenger receptor class B type I (SR-BI), another cholesterol transporter, mediates passive 
cellular cholesterol export as well as import, depending on the cholesterol gradient 73,85. The 
main function of SR-BI is cholesterol uptake into hepatocytes and steroidogenic tissues 83.  
SR-BI is also expressed by macrophages and endothelial cells, where it mediates cholesterol 
efflux to HDL. Besides cholesterol trafficking, HDL binding to SR-BI induces several protein 
kinases such as Akt or mitogen activated protein kinase (MAPK). These pathways increase 
insulin sensitivity, reendothelialization, and NO-mediated vasorelaxation in the endothelium 
85. The latter is also induced by the interaction of HDL with ABCG1 67.   
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Hepatic lipase hydrolyzes preferentially TG and to some extent PL in HDL 72,73. TG-enriched 
HDL (a result of CETP action) are excellent substrates for HL, generating small, core-lipid 
depleted HDL with unstable apoA1 binding. Endothelial lipase (EL) preferentially hydrolyzes 
HDL PL. EL reduces the size of HDL moderately, whereby the association of apoA1 is not 
attenuated. EL captures HDL on the endothelium and thereby facilitates the transport of HDL 
through the endothelium 86. This is necessary for reverse cholesterol transport.  
Sphingosine-1-phosphate (S1P), an active lipid mediator transported by HDL, interacts with 
S1P receptors. The S1P receptor isoforms are G protein-coupled receptors that induce diverse 
signaling pathways in different cell types 85. Among other functions, S1P supports proliferation 
and survival, and interferes with inflammatory signaling cascades. In -cells, extracellular S1P 
was described as protective agent against cytokine-induced apoptosis 87,88.  
 
4.3.5.   Alterations of Lipoprotein Metabolism, HDL Structure and Function in 
Metabolic Diseases 
Diabetic dyslipidemia is characterized by increased levels of VLDL triglycerides, reduced levels 
of HDL cholesterol, and increased levels of small dense LDL 89. In insulin resistance, lipoprotein 
lipase activity in muscle cells was described to be reduced. Therefore chylomicron remnants 
deliver more TG to the liver which in turn secrets more VLDL. The elevated VLDL TG levels 
promote the exchange for CE with HDL and LDL mediated by CETP. Thus, TG are hydrolyzed 
from HDL and LDL by HL leaving smaller and denser lipoproteins 90. Small dense LDL are more 
atherogenic compared to normal LDL, whereas small dense HDL are unstable and rapidly 
degraded. Besides the loss in particle stability, TG-enrichment of HDL in type 2 DM often 
implies decreased anti-inflammatory, antioxidative, and vasodilatory effects 67. 
In the insulin resistant state, insulin loses its effect in the suppression of lipolysis. This leads to 
increased levels of free fatty acids in circulation. Elevated free fatty acids decrease the 
expression of ABCA1 and ABCG1 in various cells 91. This decreases HDL levels in circulation. 
Additionally, non-enzymatic glycation of HDL apolipoproteins was found in people with 
chronically elevated blood glucose levels 72. The glycated apolipoproteins had lost their ability 
to interact with enzymes such LCAT which reduced the stability of HDL. Moreover, the 
inflammatory cytokine TNF- inhibited SR-BI- and ABCA1-mediated cholesterol efflux from 
adipocytes to HDL and apoA1, respectively 92. This further decreased HDL levels.  
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Alongside with the decrease in total HDL levels observed in subjects with metabolic syndrome, 
changes in apolipoprotein composition were found in patients with type 2 DM 93, acute 
coronary syndrome (ACS), and stable coronary artery disease (CAD) 77. HDL of both, ACS and 
CAD patients, was enriched with the pro-apoptotic apoC3, whereas the anti-apoptotic apoJ 
was decreased. Furthermore, a causal link was established between endothelial cell apoptosis 
and apoC3 as well as apoJ in that study.  
Myeloperoxidase, which is elevated in the plasma and HDL of CAD patients, oxidizes HDL and 
apoA1 67. Oxidation compromises the cholesterol efflux potential of HDL and apoA1. 
Moreover, oxidized HDL and apoA1 become pro-atherogenic, as they induce NF-B activation 
and VCAM-1 (vascular cell adhesion molecule 1) expression in endothelial cells.  
Low grade systemic inflammation, which is present in patients with perdidontitis, was found 
to change the endothelial protective properties of HDL as well 94. Compared to HDL from 
healthy donors, HDL from peridontitis patients provoked less PON1 activity in serum, less NO 
release, and more superoxide production in endothelial cells. Upon an acute inflammatory 
stimulus in the peridontitis patients, HDL temporarily contained higher levels of prothrombin 
as well as the acute phase proteins serum amyloid A (SAA) and complement factor C3. These 
changes in HDL composition were accompanied by an acute deterioration of the endothelial 
protective HDL functions (i.e. decreased NO production and PON1 activity, increased 
superoxide production). Whilst no change in cholesterol efflux from macrophages was found 
between the HDL samples of this study, the changed HDL properties in an inflammatory 
condition could impair the protective effects of HDL on -cells.  
Type 2 DM patients often suffer from chronic kidney disease (CKD). Mild CKD in children 
already induced changes in HDL composition which impaired the protective actions of HDL on 
endothelial repair and relaxation 95. In this study, symmetric dimethylarginine (SDMA) was 
found in HDL isolated from CKD patients. Moreover, SDMA was sufficient to obliterate the 
protective HDL functions on the endothelium. Another study with adult type 2 DM patients 
reported that HDL lost its anti-inflammatory activity gradually with the progression of CKD 96. 
Blood monocytes pretreated with HDL from healthy donors secreted significantly less TNF- 
in response to lipopolysaccharides than monocytes pretreated with HDL from type 2 DM 
patients among which the stimulation of TNF- was most pronounced with end stage CKD. 
Moreover, HDL of the latter patient group was found to have the highest concentration of 
SAA. In response to chronic inflammation, SAA can replace apoA1 and PON1 in HDL 67. The 
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consequences of this substitution for cholesterol efflux are controversial. However, the 
antioxidative effect of SAA enriched HDL was found to be decreased. Furthermore, SAA 
enriched HDL stimulated the release of inflammatory cytokines from vascular smooth muscle 
cells.  
 
4.3.6.  HDL Functions in Health and Disease 
Reverse cholesterol transport (RCT) is the best studied function of HDL. About 50 years ago, 
the negative association between HDL cholesterol plasma levels and the risk of developing 
coronary artery disease (CAD) was discovered and reviewed 97,98. HDL-mediated RCT was 
presumed to be the protective mechanism for the removal of excess cholesterol from 
macrophage foam cells in the atherosclerotic plaque. Cholesterol is loaded on HDL by the 
interaction with ABCG1 and SR-BI on the cell surface. To access the foam cells, HDL has to 
cross the endothelium. ABCG1 and SR-BI were shown to be involved in the HDL uptake by as 
well as the transport of HDL through the endothelium 99. However, the detailed itinerary of 
HDL through endothelial cells, which involves dynamin and the cytoskeleton, remains to be 
clarified 100. Especially the fact that HDL did not traffic the cells by the classical endocytic 
pathways (i.e. clathrin coated pits, caveolae, or fluid phase), and HDL’s intracellular allocation 
to unknown vesicular organelles need further investigation.  
It was found by in vitro and in vivo studies that HDL reduces the expression of adhesion 
molecules for monocytes (e.g. VCAM-1) in endothelial cells 67. These are upregulated by 
inflammatory cytokines on the endothelium and facilitate monocyte infiltration, an early 
event in atherosclerosis. Moreover, HDL can scavenge molecules which are harmful to cells 
such as lipopolysaccharides or oxidized lipids 79. Whereas oxidized LDL and their uptake by 
macrophages are pro-atherogenic, the oxidation of LDL is prevented by PON1 and other 
antioxidative enzymes carried by HDL 67.  
Other beneficial effects of HDL on the endothelium include the promotion of the endothelial 
barrier function and re-endothelialization after injury 95. Moreover, HDL promotes the 
proliferation of vascular smooth muscle cells. These cells stabilize atherosclerotic plaques and 
have anti-thrombotic properties. HDL protects endothelial cells from oxidized LDL, TNF- and 
serum deprivation induced apoptosis 67,77.  
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The above mentioned protective functions were collected from experiments with HDL from 
healthy donors. As discussed in section 4.3.5., numerous studies have shown that HDL is 
subjected to structural and compositional changes in subjects with chronic diseases such as 
metabolic syndrome, diabetes, atherosclerosis, and chronic kidney disease 79. It is plausible, 
that the decreases in HDL levels and functionality as consequences of the above mentioned 
conditions hamper the protective effects of HDL. Moreover, the resulting dysfunctional HDL 




4.4. Antidiabetogenic Functions of HDL 
A low HDL-C level is a well-established risk factor for the development of type 2 DM 101,102. The 
issue whether this association reflects causality has been addressed by several Mendelian 
randomization studies that yielded contradicting results. Haase and colleges found no causal 
association between the development of type 2 DM and genetic mutations which reduce the 
levels of HDL in a prospective study 103. They concluded that the observed low HDL-C levels in 
patients with type 2 DM would be a consequence of alterations in lipid metabolism secondary 
to type 2 DM. Otherwise, Fall et al. and White and colleges both described an inverse 
relationship between HDL-C levels and type 2 DM, as well as LDL-C and type 2 DM 104,105. A 
recent study that combined metabolomics with Mendelian randomization found presumably 
causal associations between the CE and FC levels of very large and large HDL particles, and 
HDL-C with low glucose levels 106. Moreover, the TG content of small HDL particles as well as 
total TG levels were positively correlated with blood glucose levels, the latter even correlated 
with type 2 DM. In addition, the protective functions of HDL on -cell survival and secretory 
function as well as on peripheral insulin resistance are under investigation.  
 
4.4.1. -Cell Survival 
Apoptosis pathways relevant for -cells in type 2 DM are described in section 4.2.4 above. 
Diverse -cell protective effects of HDL and its components have been identified to date 91. 
HDL prevented primary murine islet-cells as well as TC3 cells (a mouse -cell line) from 
apoptosis induced by supraphysiological LDL concentrations 107. In Min6 cells (another mouse 
-cell line) oxidized LDL-induced apoptosis was prevented by simultaneous incubation with 
HDL 108. In the same cell line, protective effects of HDL were described against starvation-,  
IL-1-, thapsigargin-, and tunicamycin-induced apoptosis 109. Whereas HDL-mediated 
protection against starvation- and IL-1-induced apoptosis involved the modulation of the 
expression of the translation regulator 4E-BP1, the ER stress inducers thapsigargin and 
tunicamycin did not.  
Our research group previously demonstrated a protective effect of HDL against apoptosis 
induced by high glucose concentrations in primary human and murine -cells 88. Moreover, 
we found an anti-apoptotic effect for HDL as well as for its components apoA1 and S1P against 
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IL-1-induced apoptosis. That apoA1 was found to increase the expression of the survival gene 
Pdx-1 in INS-1E cells could provide a possible explanation for this finding 110.  
Surprisingly, differences in the protective effect of HDL against different ER stressors have 
been described. HDL resolved both, ER stress and apoptosis, if induced by thapsigargin (an 
inhibitor of the SERCA Ca2+ pump), palmitate or insulin overexpression 111. In contrast, ER 
stress-induced apoptosis by tunicamycin (a protein glycosylation inhibitor) was prevented by 
HDL without resolving the ER stress 112.  
 
4.4.2. Promotion of Insulin Secretion  
HDL and apoA1 mediate cholesterol efflux from -cells. A disturbed basal and glucose-
stimulated insulin secretion was reported in apoE-deficient mice which have elevated 
cholesterol levels in circulation as well as in pancreatic islets 113. Interestingly, insulin secretion 
was normalized when cholesterol overload was treated systemically in mice with statins or 
acutely in islets where cholesterol was depleted with methyl--cyclodextrin. In this study, 
insulin secretion was correlated with the dimerization of neuronal NO synthase and the 
activity of glucokinase. Additionally, the importance of cholesterol efflux for insulin secretion 
was demonstrated in a study with mice having a -cell specific knock-out of ABCA1 114. 
Although these mice had a normal lipoprotein profile, their glucose tolerance was massively 
deteriorated compared to their control littermates. Presumably, this was caused by a loss of 
first-phase insulin secretion. Glucose tolerance was further impaired in ABCG1 knock-out mice 
crossed with the -cell specific ABCA1 knock-out 115. Whereas plasma cholesterol levels were 
not changed in these mice, the defect in insulin secretion was associated with increased islet 
cholesterol accumulation. Consequences of ABCG1 deficiency alone were mild or not 
observed in this study. Since insulin secretion in response to potassium chloride was impaired 
in islets of mice with combined absence of ABCG1 and ABCA1, the authors concluded that the 
cholesterol accumulation induced a defect in insulin granule exocytosis. Moreover, 
cholesterol accumulation was associated with IL-1 expression in islets and macrophage 
infiltration. -cell specific ABCA1 knock-out mice also showed changes in the organization of 
cholesterol-enriched membrane microdomains, changes in the Golgi ultrastructure, and 
impaired insulin processing 116. It is plausible that these effects were exacerbated by the 
combined loss of ABCG1 and ABCA1 in -cells. Whereas acute cholesterol depletion with 
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methyl--cyclodextrin restored insulin granule exocytosis in the absence of ABCA1 116, methyl-
-cyclodextrin-mediated cholesterol desorption had been shown to decrease the exocytotic 
response in -cells in an earlier study 117. In addition, an intracellular role for ABCG1 was 
described 118: ABCG1 deficient mice were less glucose tolerant than wild type controls, 
whereas total cholesterol content of islets was not changed. However, -cell ABCG1 was 
predominantly found in the secretory vesicles, and the subcellular cholesterol distribution was 
different, with ABCG1 deficient -cells having less cholesterol in secretory vesicles than wild 
type -cells. The authors postulated therefore that ABCG1 is responsible for the regulation of 
the cholesterol content of secretory vesicles in -cells. A more recent study with -cell-specific 
ABCA1- and ABCG1-deficient mice confirmed the necessity of these two receptors as well as 
their role in cholesterol homeostasis for proper insulin secretion 119. Moreover, the decreased 
insulin secretion caused systemic inflammation and shifted glucose disposal from muscle cells 
to adipocytes. An elegant study investigated the mere event of insulin granules fusing with 
the plasma membrane in a full manner or as kiss-and-run event 120. The authors could 
demonstrate that cholesterol overload shifts the fusion events towards kiss-and-run events 
that are far less efficient in insulin release. This could provide an explanation for the defects 
observed in type 2 DM which are often associated with elevated plasma cholesterol.  
An association of HDL-C levels and -cell secretory function was found in a study of subjects 
with heterozygous mutations in ABCA1 that have 50% less HDL-C but otherwise a normal lipid 
profile 121. Their first-phase insulin secretion was decreased in a hyperglycemic clamp 
experiment compared to relatives that are non-carriers of the mutation. This finding was 
challenged by Rickels and colleges who found an association of hetero- or homozygote ABCA1 
deficiency with improved insulin secretion 122. One possible explanation for the contradictory 
results is the mean age of the study subjects which was 27 years in Rickels’ study vs. 54 years 
in Vergeer’s study 123. It is plausible that the duration for which subjects had been exposed to 
low HDL levels shifted the cholesterol homeostasis of -cells from a favorable to a deleterious 
side. Moreover, infusion of reconstituted HDL (i.e. lipidated apoA1) improved insulin secretion 
and enforced glucose uptake in healthy individuals 124. Also in mice, single doses of apoA1 
improved glycemic control, possibly by priming of the -cells for glucose-stimulated insulin 
secretion 125. Preincubation of INS-1E cells with an apoA1 derived short peptide (C-terminal 
domain) or a single dose of this peptide in diet induced obese mice improved glucose induced 
insulin secretion or insulin secretion in a glucose tolerance test, respectively 126.  
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CETP inhibitors decrease HDL catabolism and thereby raise HDL levels. This has been shown 
for five different CETP inhibitors, though the expected decreased risk for cardiovascular 
disease events has not been established in large randomized trials yet 127. In healthy 
individuals, CETP inhibitor treatment increased HDL-C levels within two weeks 128. This 
increase in HDL-C was associated with increased postprandial insulin levels. ApoB-depleted 
plasma of CETP inhibitor-treated subjects stimulated glucose-stimulated insulin secretion 
from a-cell line to a larger extent than the apoB-depleted plasma from the placebo-treated 
group. This effect was probably caused by the increased cholesterol efflux mediated by the 
CETP inhibitor plasma. Post-hoc analysis of the ILLUMINATE trial revealed lower fasting 
glucose and insulin levels as well as a decrease in glycated hemoglobin (HbA1c) in the diabetic 
subgroup of the cohort receiving CETP inhibitor with statin treatment compared to the 
diabetic subgroup receiving statin only treatment 129. These effects did not correlate with the 
increase in HDL-C, however. Therefore, it remains to be clarified how CETP inhibition improved 
glycemic control. 
Besides its role in cholesterol homeostasis, apoA1 – although at supraphysiological doses – 
was found to increase insulin production by nuclear exclusion of an insulin repressor in INS-1E 
cells 110.  
Several studies found an increased risk for type 2 DM in persons with statin treatment 130. 
Statins reduce cholesterol synthesis by inhibition of the HMG-CoAR at the cellular level. In 
Mendelian randomization studies, loss of function mutations in the HMG-CoAR gene were 
associated with an increased risk for type 2 DM 131,132. By contrast, patients with familial 
hypercholesterolemia were found to have a reduced risk of diabetes notwithstanding their 
life-long statin treatment. One plausible explanation for this association is the upregulation of 
LDLR in peripheral cells, including -cells, and subsequent cholesterol overload of these cells 
despite low levels of cholesterol in the bloodstream. Statin treatment could affect the fragile 
cholesterol balance in -cells and decrease insulin secretion. Moreover, direct effects of 
statins on Ca2+ channels in -cells have been reported which could explain the defects in 
insulin secretion associated with statin therapy 133. Another proposed effect of lipophilic 
statins on insulin secretion is the cholesterol depletion of -cells. This disturbs lipid rafts in the 
cell membrane and thereby interferes with Ca2+ channels. Since the authors found an 
association with body weight as well, it seems well possible that peripheral increased insulin 
resistance is involved in the elevated risk for type 2 DM.  
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The effects of proprotein convertase subtilisin/kexin type 9 (PCSK9), which increases the 
degradation of LDL receptors on hepatocytes and thus rises LDL levels in the blood stream, on 
glucose metabolism was investigated by several studies 134. Whereas Langhi et al. could not 
find a negative effect of PCSK9 deficiency on glucose metabolism in mice, male PCSK9-
deficient mice were reported to be hyperglycemic, hypoinsulinemic, and glucose-intolerant at 
the age of 4 months while their pancreatic islets exhibited decreased insulin content and 
morphological abnormalities compared to islets of PCSK9-positive mice 135,136. Mendelian 
randomization studies on PCSK9 variants found an association between the decreased LDL 
levels in circulation and an increased risk for type 2 DM 132,137. Otherwise, Baass et al. even 
found a positive correlation of PCSK9 levels with fasting insulin levels in children, indicating a 
negative effect of PCSK9 on glucose homeostasis 138. To date, clinical studies could not clarify 
whether PCSK9 inhibition or deficiency results in positive, negative or neutral effects on 
glucose metabolism 139.   
In summary, cholesterol homeostasis of -cells and their secretory vesicles seems to be 
important for insulin secretion. HDL which functions as cholesterol donor and/or acceptor 
depending on the cholesterol status of the cell might stabilize this balance. 
 
4.4.3. Peripheral Insulin Resistance  
In obesity, the permanent abundance of nutrients induces several stress-responsive signaling 
pathways in adipocytes, hepatocytes, and muscle cells. Most of these pathways converge in 
the inhibition of insulin signaling through serine-phosphroylation of insulin receptor substrate 
and the promotion of inflammation in the above mentioned tissues 140. Local inflammation 
activates resident macrophages that secrete inflammatory cytokines and recruit additional 
leukocytes. Thus, systemic inflammation, which induces insulin resistance, is sustained in a 
deleterious feed-forward signaling loop. Since low HDL-C levels were identified as an 
independent predictor for future insulin resistance in prospective studies 141,142, and since HDL 
exerts anti-inflammatory effects on macrophages, HDL may serve as an important protector 
against insulin resistance 143.  
In adipocytes, a reduction of chemotactic factors for macrophages (i.e. monocyte 
chemoattractant protein 1 (MCP-1) and serum amyloid A (SAA) 3) was found after the 
administration of HDL or apoA1 144. These effects were mediated by ABCG1- and SR-BI-, or 
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ABCA1-dependent cholesterol efflux, respectively. Moreover, in the adipose tissue of mice 
over-expressing apoA1 on high fat diet, the expression of SAA3, MCP-1, as well as 
inflammatory cytokines interleukin 6 and TNF- was reduced compared to wild type mice on 
high fat diet. By these means, HDL possibly increased insulin sensitivity in adipocytes.  
In response to a high-fat diet, mice developed systemic and hepatic inflammation, insulin 
resistance, and reduced glucose tolerance 145. These symptoms were prevented by the 
infusion of apoA1 in mice, whereas cholesterol efflux from hepatocytes mediated by methyl-
-cyclodextrin was not sufficient to reduce inflammation and improve insulin sensitivity. 
Moreover, an association with the activation of nuclear factor kappa B (NF-B) was found: NF-
B was upregulated by the high-fat diet, and this up-regulation was attenuated by apoA1 
infusion. The same pattern was found for the inflammatory cytokines TNF-, IL-6, and IFN- 
which are regulated by NF-B activation.  
In cultured myocytes, an apoA1 derived short peptide (C-terminal domain) induced glucose 
uptake dose-dependently 126. A single dose of this peptide in diet induced obese mice or mice 
with a deficient leptin receptor (db/db mice) significantly improved glucose clearance in a 
glucose tolerance test, possibly by increased glucose uptake in muscle cells.  
 
4.4.4. AMPK Functions 
Besides insulin stimulated glucose uptake, AMP-activated protein kinase (AMPK) mediated 
glucose uptake in muscle cells and adipocytes seems to be important for glucose  
homeostasis 143. In adipocytes, HDL was found to enhance glucose uptake by the increase of 
glucose transporter GLUT-4 translocation to the cell surface 146. This facilitated glucose uptake 
and lowered blood glucose levels. GLUT-4 translocation was associated with AMPK and PI3K 
signaling which probably was activated by HDL binding on SR-BI.  
In muscle cells, apoA1 and HDL stimulated AMPK and increased glucose uptake 124,147. Since 
skeletal muscle cells are responsible for the majority of glucose uptake, its stimulation by HDL 
is important for glucose homeostasis. As for adipocytes, discoidal HDL was described to 
promote the translocation of glucose transporter GLUT-4 in myocytes 148. Additionally, 
glycogen synthesis in muscle cells was stimulated by HDL 146, and glucose oxidation was 




Also in hepatocytes, where insulin-mediated suppression of gluconeogenesis is lost in insulin 
resistance, an interaction of HDL and AMPK was found: ApoA1 activated AMPK in hepatocytes 







4.5. Aim of this Study 
At physiological circumstances, hyperglycemia is compensated by an increase in -cell mass 
and function. Type 2 diabetes mellitus manifests at the point where this compensation 
collapses and insulin resistance cannot be counterbalanced. Moreover, pre-diabetic subjects 
often exhibit a shift in their lipoprotein profile towards low plasma levels of HDL cholesterol, 
a high TG concentration, and an elevated fraction of small dense LDL. Instead of being a mere 
consequence of insulin resistance, the decreased HDL levels could expose those people at 
increased risk for the manifestation of type 2 DM. Several lines of evidence nowadays indicate 
a causal link between HDL and the pathogenesis of type 2 diabetes mellitus.  
During the manifestation of type 2 DM, -cell apoptosis is a major process. Our lab has 
previously shown that HDL prevents IL-1-induced apoptosis of primary human and mouse 
pancreatic -cells 88. Moreover, it was described that apoA1 and S1P could mimic the 
protective effect of HDL. However, the mechanism behind the protective effects remained 
largely unknown.  
Therefore, the main goals of this thesis are:  
1) The confirmation of the described protective components of HDL, and the identification 
of components of HDL that are responsible for its beneficial effect on -cell apoptosis. 






5. Materials and Methods 
5.1. Cell Culture 
5.1.1. INS-1E Cells 
The INS-1 cell line was grown from a radiation-induced rat insulinoma tumor 150. The clonal 
INS-1E cell line was selected from the INS-1 cells according to their responsiveness to glucose 
by Prof. C Wollheim and his group 151. He kindly provided our lab with these cells.  
The INS-1E cells were cultured in 10 cm cell culture plates with RPMI 1640 medium (11.1 mM 
glucose) supplemented with 10% heat inactivated fetal bovine serum (FBS), 2 mM  
L-glutamine, 1% PenStrep (i.e. 100 IU/ml Penicillin, 100 g/ml Streptomycin), 10 mM HEPES, 
1 mM NaPyruvate, and 0.05 mM 2-mercaptoethanol (all purchased from Sigma-Aldrich, St. 
Louis MO, USA) as cell culture medium. Cells were split once per week by gentle trypsinization 
(Trypsin-EDTA 10x, diluted to 1x with PBS, Sigma-Aldrich) and seeded at 2 to 2.75*106 cells 
into fresh 10cm-plates. We used the cells between passages 58 and 68. During experiments 
with HDL, FBS was replaced by delipidated FBS. FBS was delipidated by ultracentrifugation as 
follows: The density of FBS was adjusted to 1.21 g/ml by the addition of KBr. After 20 hours of 
centrifugation (59000 rpm; system L90K, Beckman Coulter Inc., Brea CA, USA), the top 1.5 cm 
liquid were discarded. The lipid-free part was dialyzed (seven steps within 72 hours in 0.9% 
NaCl solution). The delipidated FBS was filter sterilized (0.22 m microfilter, Millipore 
Corporation, Billerica MA, USA) and frozen in aliquots at -80 °C. 
 
5.1.2. Min6 Cells 
Min6B1 cells (referred here as Min6) were derived from a mouse insulinoma tumor 152. They 
were cultured in 10cm cell culture plates in DMEM medium supplemented with 15% heat-
inactivated FBS, 0.06 mM 2-mercaptoethanol and 1% PenStrep (i.e. 100 U/ml Penicillin,  
100 g/ml Streptomycin), all purchased from Sigma-Aldrich. Cells were split 1:5 twice per 




5.1.3. J774 Cells 
The murine macrophage cell line J774 (ATCC, Rockville MD, USA) was cultured in 10 cm 
bacterial culture plates in RPMI 1640 medium supplemented with 10% FBS and 1% PenStrep 
(i.e. 100 U/ml Penicillin, 100 g/ml Streptomycin), all purchased from Sigma-Aldrich. Cells 






5.2.1. Lipoprotein Isolation 
Normolipidemic plasma obtained from a blood donor bank (Blutspende Zürich, Schlieren, 
Switzerland) was used to isolate lipoproteins. HDL (density: 1.063-1.210 g/ml) and LDL 
(density: 1.019-1.063 g/ml) was isolated by sequential density ultracentrifugation. Potassium 
bromide (KBr) and ethylenediaminetetraacetic acid (EDTA) were added before each 
centrifugation step (59000 rpm; system Optima L90K, Beckman Coulter Inc., Brea CA, USA) to 
adjust the correct density. After isolation, the KBr was removed from lipoprotein fractions by 
dialysis (five steps within 48h; buffer containing 0.15 M NaCl, 0.3 mM EDTA, pH 7.4). Finally 
the lipoprotein preparations were filter sterilized (0.22 m microfilter, Millipore Corporation, 
Billerica MA, USA). The protein concentration of the isolated HDL and LDL preparations were 
measured with the DC assay (Bio-Rad, Hercules CA, USA), against a standard-curve with bovine 
serum albumin. To assess the purity of HDL, the lipoprotein preparation was run in a sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) with subsequent Coomassie 
blue staining of the gel. Only HDL preparations without visible contaminations of apoB nor 
albumin were used for experiments.  
From low volume plasma or serum samples of the clinical studies or mouse experiments, HDL 
was isolated by using 2 ml centrifuge tubes for sequential ultracentrifugation (Optima  
Max-TL, Beckman Coulter Inc.). According to this protocol, 500l plasma or serum were 
combined with 1000 l 0.150 M NaCl / 1 mM EDTA solution and 500l 38% KBr solution. This 
mixture with a density of 1.068 g/cm3  was filled into the small centrifuge tubes. After 6 hours 
centrifugation at 120'000 rpm (4 °C), the tubes were cut at 10mm from the bottom. The LDL 
at the top was collected and the density of the lower fraction was set to 1.21 g/cm3  by the 
addition of 900 l 46.5% KBr solution. After overnight centrifugation at 120'000 rpm (4°C), the 
tubes were cut at 15 mm from the bottom. The HDL at the top of the tube was collected, 
dialyzed, and analyzed as described above.  
 
5.2.2. Extraction of HDL Protein and Lipid Moieties 
HDL was dialyzed against 0.9% NaCl-solution, lyophilized, and subsequently extracted with an 
ice-cold chloroform-methanol (2:1, vol:vol) mixture. The dispersion was incubated in an 
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ultrasonic water bath, and thereafter incubated on ice. Methanol was added to precipitate 
the HDL protein moiety and the proteins were pelleted by centrifugation.  
The supernatant which contained the HDL lipid moiety was transferred to a new tube and the 
solvents were evaporated under N2 flow. The dried HDL lipids were dissolved in ethanol before 
adding to cells.  
The protein pellet was washed twice with ice-cold ethanol and centrifuged. The proteins were 
lyophilized. Before adding the HDL proteins to cells, they were dissolved in guanidinium 
hydrochloride (5 M) and dialyzed in buffer containing 0.15 M NaCl, 0.3 mM EDTA, pH 7.4.  
 
5.2.3. Apolipoproteins and Lipids 
Apolipoprotein A1 (apoA1) was purified from delipidated HDL solubilized in urea (6M) and Tris 
(10 mM, pH 8) using an anion exchange column (MonoQ) on an Äkta Protein Purification 
System (GE Healthcare, Life Sciences, Buckinghamshire, UK). Bound HDL proteins were eluted 
using a gradient of 0 to 150 mM NaCl in 5 M urea, and 10 mM Tris (pH 8), as previously 
described 153. The eluted proteins were collected in small fractions. All fractions were dialyzed 
and analyzed by SDS-PAGE and Coomassie blue staining. The pure apoA1 fractions were 
pooled. The fractions containing other proteins beside apoA1 were collected for another 
apoA1 purification cycle, or analyzed for their anti-apoptotic potential.  
Purified apolipoprotein C1 (apoC1) and apolipoprotein E (apoE) were purchased from Athens 
Research & Technology (Athens GA, USA) and reconstituted in deionized water to 2 mg/ml 
stock concentration. Recombinant apolipoprotein D (apoD, expressed in HEK cells) was 
purchased from OriGene Technologies (Rockville MD, USA; 0.242 g/ml stock concentration). 
Sphingosine-1-phosphate was purchased from Avanti (Avanti Polar lipids, Alabaster AL, USA). 
It was dissolved in DMSO/1 M HCl (95:5%, vol:vol) and subsequently diluted in 3% BSA/PBS to 
1 mM stock concentration.  
 
5.2.4. Lipidation of ApoA1 
ApoA1 was lipidated by the cholate dialysis method 154. Purified apoA1, 2-oleoyl-1-palmitoyl-
sn-glycero-3 phosphocholine (POPC, Sigma-Aldrich), and sodium cholate (Sigma-Aldrich) were 
mixed in a molar ratio of 1/40/80. First, POPC (dissolved in chloroform) was dried in a glass 
tube under N2-flow, then it was dissolved in Tris saline buffer (0.01 M Tris, 0.15 M NaCl,  
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0.1 mM EDTA, pH=8). The POPC-Tris mixture was vortexed thoroughly and incubated  
30 minutes on ice. Then, sodium cholate was added and to induce the formation of micelles, 
this mixture was vortexed every 10 minutes during 30 minutes until the mixture cleared. 
ApoA1 was added to the micelles in Tris saline buffer and the mixture was incubated  
90 minutes on ice. Finally, the mixture was extensively dialyzed in buffer containing 0.15 M 
NaCl, and 0.3 mM EDTA at pH 7.4 for 48 hours at 4 °C in tubes with a cutoff of 50’000 Da 
molecular weight to remove free apoA1.  
 
5.2.5. Acetylation of LDL 
For the acetylation of LDL, 5 mg LDL protein was diluted with buffer containing 0.15 M NaCl 
and 0.3 mM EDTA (pH 7.4) to a final volume of 2 ml and mixed with 2 ml ice-cold saturated 
sodium acetate. After 15 minutes stirring at 4 °C, 80 l acetic acid was added in portions of  
10 l every 15 minutes. Then, the mixture was incubated 30 minute at 4 °C. The acetylated 
LDL was dialyzed in four steps within 48 hours against buffer containing 0.15 M NaCl, 0.3 mM 





5.3. RNA Analyses 
5.3.1. RNA Isolation with TRI-reagent 
INS-1E RNA was isolated from 12- or 6-well dishes containing 4*105 or 1*106 cells per well, 
respectively. The medium was removed and the cells were lysed with TRI reagent (0.5 ml or  
1 ml respectively; Sigma-Aldrich, T9424). The suspension was sheared with a pipette. The 
lysate was transferred to an Eppendorf tube and mixed with 0.1 or 0.2 ml chloroform. After 
thorough mixing and incubation on ice, the water and organic phase were separated by 
centrifugation. The water phase on top was transferred to a fresh tube. To this tube, 
isopropanol (0.5 ml per ml TRI reagent) was added to precipitate the RNA. After 
centrifugation, the pellet was washed with 75% ethanol and dried. The pellet was 
subsequently solubilized in DEPC-treated water and heated 10 minutes at 65 °C to ensure 
proper dissolving of the RNA. The RNA content was determined with the Nanodrop 
(ThermoFischer Scientific, Wilmington DE, USA). Finally, RNA was subjected to DNA digestion 
with DNase (Roche, Basel, Switzerland).  
 
5.3.2. RNA Isolation with Silica-Colums 
RNA for gene array analysis was isolated from cells after the induction of apoptosis with the 
Illustra-Kit (GE Healthcare, Life Sciences, Buckinghamshire, UK). In brief, cells in the 6-well dish 
(8*105 cells per well) were washed twice with phosphate buffered saline (PBS). 350 l 
provided lysing solution was added and cells were scraped off the well. The lysate was sheared 
with a syringe and transferred to the silica column. Then the RNA isolation and DNA digestion 
were performed according to the instructions of the manufacturer. As last step of the 
isolation, the RNA was eluted in 30 l RNase-free water.  
 
5.3.3. Reverse Transcription 
The transcription of the isolated RNA was done with SuperScript II (LifeTechnologies, Carlsbad 
CA, USA) or RevertAid (ThermoFischer Scientific, Wilmington DE, USA) according to the 




5.3.4. Polymerase Chain Reaction 
The polymerase chain reaction (PCR) was performed with Taq polymerase (Roche, Basel, 
Switzerland) and the primers described in table 5.1. The PCR products were analyzed by  
1% agarose gel electrophoresis.  
 
5.3.5. Quantitative Polymerase Chain Reaction 
For the quantification of specific RNAs, the LightCycler system (Roche, Basel, Switzerland) was 
used. We used the LightCycler mix (Roche, Basel, Switzerland) containing the polymerase 
enzyme and required dyes. The primers are listed in table 5.1. GAPDH was used for 
normalization. The data was quantified by using the extended “delta-delta CT” method 
according to M.W. Pfaffl 155.  
 
5.3.6. RNA Analysis with Agarose Gels 
After isolation of RNA with silica columns (see above), the integrity of the isolated RNA was 
analyzed by electrophoresis on a 1.5% agarose gel. The appearance of distinct 18S and 28S 
rRNA bands was taken as quality sign for the total isolated RNA. Good quality RNA samples 
were used for the gene array at the Functional Genomics Center Zürich (FGCZ). 
 
5.3.7. Gene Array 
The gene array, including labelling and hybridization of the RNA, was performed by the FGCZ. 
The SurePrint G3 Rat GE 8x60K Microarray (Agilent Technologies, Santa Clara CA, USA) was 
chosen for the analysis of the whole gene expression.  
The gene array data was normalized and annotated by the FGCZ. Subsequent analyses were 
done by using the MetaCoreTM software (Genego, Thompson Reuters, New York, NY, USA) and 






5.3.8. Primer Specifications 






Fwd AAG CTG TGG CGT GAT GGC CG 
117 60 
Rev GGC CAT GCC AGT GAG CTT CCC 
Rat ATF6 
Fwd AGA CTG GGA GTC CAC GTT GTT T 
152 60 
Rev GGC TCC ATA TGT CTG ACT CCC 
Rat  
Bcl-xL 
Fwd GAT GGG GTA AAC TGG GGT CG 
182 60 
Rev TCC ACA AAA GTG TCC CAG CC 
Rat BIM 
Fwd CCG GTC CTC CAG TGG GTA TT 
133 60 
Rev TAT GGA AGC CAT TGC ACT GAG A 
Rat CFLAR 
Fwd GGG ACC TCC TGG ATT GTT TAA GTG 
179 60 
Rev CAG CAG CAC CCT ATA ATC GGA A 
Rat CHOP 
Fwd TTC ACT ACT CTT GAC CCT GCA TC 
176 60 
Rev CAC TGA CCA CTC TGT TTC CGT TTC 
Rat DP5 
Fwd GCC GTG GTG TTA CTT GGA CT 
125 60 
Rev GAT TGT GCC AGA GCT TCA CA 
Rat FAS 
Fwd GGA GGA GTA CAC GGA CAG GA 
131 62 
Rev TTT CTT TGC ACC TGC ACT TG 
Rat IL1R 
Fwd GGC TTG TGA CAT CTT CGG CT 
115 60 
Rev TAC TCC GTG CAT TTG TCG GT 
Rat STAT1 
Fwd AAG CAC CAG AAC CGA TGG AG 
88 60 
Rev GAA GGG TGG ACT TCA GAC ACA 
Rat sXBP1 
Fwd TGC TGA GTC CGC AGC AGG TG 
169 60 
Rev ATT AGC AGA CTC TGG GGA AG 





5.4. Protein Analyses 
5.4.1. Protein Isolation and Quantification  
Cells were grown in 6-well dishes with 1*106 cells per well and stimulated 24 h after seeding. 
For protein isolation, the cells were washed twice with cold PBS, scraped in PBS and 
transferred to a tube. After centrifugation, the cells were lysed in 50 l RIPA buffer (10mM 
Tris pH 7.4, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl, 
complete EDTA (Roche, Basel, Switzerland)) with protease inhibitors (Sigma-Aldrich) per well. 
After 30 minutes incubation, the lysates were centrifuged at 13’000 g to pellet the DNA. The 
lysates were then transferred to a fresh tube.  
To analyze the protein content in the lysates, the colorimetric reaction of the DC protein assay 
(BioRad) was used with a bovine serum albumin standard curve.  
 
5.4.2. Western Blotting 
Proteins from cell lysates were separated according to their size by SDS-PAGE. Thereafter, the 
proteins were transferred to a PVDF membrane (GE Healthcare) with wet or semi-dry 
electroblotting systems.  
After incubation with the respective antibodies (see table 5.2), the specific proteins were 
detected with Pierce ECL plus (Thermo Scientific) and subsequent exposure of films 
(Amersham Hyperfilm ECL, GE Healthcare). Alternatively, western blots incubated with 
secondary antibodies which emit light in the infrared spectrum, were recorded in the Odyssey 
infrared image system (LI-COR Biotechnology, Lincoln NE, USA). 
 
5.4.3. Analysis of HDL Protein Composition with Mass-Spectrometry 
LC-ESI-MS/MS analyses of the protein composition of the HDL protein fractions were done by 
my colleague Meliana Riwanto 77. In brief, the fractions from the FPLC (see above) were 
digested by trypsin. The peptides were lyophilized and resolubilized in 0.1% trifluoroacetic 
acid (TFA). Samples were analyzed on a hybrid LTQ-Orbitrap mass spectrometer 
(ThermoFischer Scientific, Wilmington DE, USA) interfaced with a nanoelectrospray ion 
source. Chromatographic separation of peptides was achieved on an Eksigent nano LC system 
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(Eksigent Technologies, Dublin CA, USA). The spectral counts were normalized by using 
internal standards for known proteins.  
 
5.4.4. ELISA for Apolipoprotein C1 
The concentration of apoC1 in plasma, apoB-depleted plasma, and HDL was measured with a 
commercial apoC1 ELISA (Abnova, Taipei, Taiwan). ApoB was precipitated from serum by the 
addition of 10% of serum volume sodium dextran sulfate and MgCl (10 g/l Na dextran sulfate, 
0.5 M MgCl, pH 7). The mixture was incubated 10 minutes at room temperature. Then, the 
precipitated apoB was pelleted by 40 minutes centrifugation at 13’000g. ApoC1 was measured 
in the supernatant, plasma, or HDL according to the manufacturer’s protocol.  
 
5.4.5. Antibody Specification 
Protein Source Antibody type Host Dilution 
Cleaved Caspase 3 
Cell Signaling  Technology 
# 9661 
Polyclonal Rabbit 1:1000 
Phospho-PERK (Thr980) 
Cell Signaling  Technology 
# 3179 
Monoclonal Rabbit 1:1000 
Tubulin (TUB 2.1) 
Sigma-Aldrich 
# T4026 
Monoclonal Mouse 1:5000 
Mouse IRDye 800CW 
LI-COR Biosciences,  
# 926-32210 
Polyclonal Goat 1:5000 
Rabbit-HRP 
Dako / Agilent Technologies  
# P0448 
Polyclonal Goat 1:5000 
Rabbit IRDye 680RD 
LI-COR Biosciences  
# 926-68071 
Polyclonal Goat 1:5000 
Table 5.2: Specifications of primary and secondary antibodies used for Western blots.  





5.5. Bioassays for Cell Function and Survival 
5.5.1. Cell Death Detection ELISA Plus 
Unless otherwise described in the results section, INS-1E cells were pre-incubated in medium 
with 10% delipidated FBS with or without HDL or the indicated proteins 24 hours after seeding 
(24-well plates with 2.5*105 cells per well). After this overnight pre-incubation, interleukin 1 
(IL-1) was added for apoptosis induction at 10 ng/ml final concentration in medium. 
Recombinant rat IL-1 was purchased from PeproTech (PeproTech EC, London, UK) or R&D 
(R&D Systems, Minneapolis MN, USA) and reconstituted in 5% BSA in PBS to 0.1 mg/ml stock 
concentration.  
24 hours later, apoptosis was quantified in the treated samples and not-treated control 
samples with the cell death detection ELISA Plus (Roche). For this assay, cells were washed 
with PBS and lysed in the buffer provided by the manufacturer which preserves the nuclei. 
Antibodies against DNA and histones detected the cytosolic DNA (a sign of apoptotic cells), 
but not the DNA in intact nuclei of healthy cells. 
Alternatively, apoptosis was stimulated in INS-1E cells after the pre-incubation by the addition 
of thapsigargin (ThG) at 50 nM final concentration for 8 hours. Thapsigargin (ThG) was 
purchased from Sigma-Aldrich (T9033) and dissolved in DMSO to 5 mM and 12.5 M stock 
solution.  
 
5.5.2. Annexin V / Phosphatidylserine Exposure 
In apoptotic cells, phosphatidylserine (PS) molecules are flipped from the inner to the outer 
membrane. Annexin V binds to this PS molecules on the cell surface of otherwise intact cells.  
Propidium iodide is used as a marker for necrotic (permeable) cells since it enters the nucleus 
of necrotic cells and stains the DNA, whereas in intact cells the DNA is not accessible for the 
propidium iodide. 
After apoptosis induction (as described above) in 12- or 24-well dishes (4 or 2.5* 105 cells per 
well, respectively), floating INS-1E cells were collected and attached cells were removed with 
accutase (Sigma-Aldrich, A6964). Thus, the cells were washed with PBS and incubated with 
accutase, 5 minutes at 37°C. Then the detached cells were combined with the respective 
floaters, washed and stained with annexin V (diluted 1:20 in FACS buffer (PBS 1x, 2% FCS, 
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0.05% NaN3, 20 mM EDTA), Annexin V labeled with AlexaFluor 647, BioLegend San Diego CA, 
USA) and propidium iodide (2.5 g/ml in FACS buffer, Propidium Iodide solution, USBiological, 
Swampscott MA, USA) in FACS buffer. The stained cells were analyzed by flow cytometry with 
a 488 nm laser for propidium iodide and a 635 nm laser for annexin V. Thus, cells could be 
differentiated into healthy cells, necrotic cells, early apoptotic cells and late apoptotic cells.  
 
5.5.3. NF-B Translocation 
INS-1E cells were grown on glass coverslips in 24-well plates with 2.5*105 cells per well. After 
16 hours incubation with or without HDL, IL-1 was added to the cells for 5 or 15 minutes,  
1, 5, or 24 hours. Afterwards, the cells were fixed with 3.75% paraformaldehyde (PFA) for at 
least 20 minutes, washed with PBS, and subsequently permeabilized with 0.5% TritonX-100. 
To visualize the translocation of the transcription factor NF-B from the cytosol into the 
nucleus, the fixed cells were incubated with an NF-B antibody (rabbit-anti-p65, polyclonal, 
#sc-372, Santa Cruz Biotechnology, Dallas TX, USA), diluted 1:200 in PBS for 1 hour at room 
temperature. After several washing steps, the cells were incubated with the secondary 
antibody (donkey-anti-rabbit polyclonal 660, CF660R, #20389, Biotium Inc., Fremont CA, USA), 
diluted 1:500 in PBS over night at 4°C. Cells were washed and mounted with the Prolong Gold 
Antifade Reagent with DAPI (LifeTechnologies, Carlsbad CA, USA). The cells were analyzed with 
a 63x magnification objective at 660 nm (NF-B) and 355 nm (DAPI).  
 
5.5.4. Pychnotic Nuclei Screening  
Min6 cells were treated 24 hours after seeding in 24-well plates (2.5*104 cells per well) with 
or without HDL or apoC1, and with or without ThG (0.5 M, T9033, Sigma-Aldrich) for another 
24 hours. After this treatment, the cells were fixed with 4% PFA and the nuclei were visualized 
with Hoechst stain (94403, Sigma-Aldrich). For analysis, at least 500 cells per condition were 






5.5.5. Active Caspase 3 Detection 
For the detection of cleaved/active caspase 3 with the specific antibody (see table 5.2), cells 
were harvested from a 6 well plate after treatment. Cells were lysed with RIPA buffer and 
concentration of proteins was determined by DC assay (see section 5.4.1.). 10 g proteins per 
sample were loaded for a western blot (see section 5.4.2.).  
For the caspase 3 activity assay (CASP3F, Sigma-Aldrich), 2.5*104 INS-1E cells were seeded in 
96-well plates. After apoptosis induction with ThG, cells were harvested by centrifugation of 
the plate (5 min, 1000 rpm, 4°C), subsequent removal of the medium and addition of 100 l 
assay buffer. The plates were then covered and frozen at -80 °C. After thawing, 80 l of the 
lysate was transferred to a black 96-well plate, mixed with the substrate (a caspase specific 
peptide conjugated to a fluorescent reporter molecule), and incubated for 60 min at 37°C. 
After cleavage of the peptide by the caspase, fluorescence was measured at the TECAN Infinite 
M200 pro series fluorescence reader (excitation at 400 nm and emission at 500 nm, Tecan, 
Männedorf, Switzerland). The level of the fluorescent signal was directly proportional to the 
level of active caspase 3 in the cell lysate.   
The protein content of the remaining lysate was detected with the Bradford reagent and a 
standard curve of BSA in assay buffer.    
 
5.5.6. Cholesterol Efflux 
For efflux experiments, J774 macrophage cells were seeded into 96-well plates and cultured 
for 24 hours. Then, the macrophages were loaded with 50 μg/ml acetylated LDL and 2 μCi/ml 
3H-cholesterol (Perkin Elmer, Schwerzenbach, Switzerland) in cell culture medium without 
FBS. 24 hours later, cell were equilibrated in medium containing 0.2% serum albumin 
supplemented with or without 0.3 mM N6,2’-O-dibutyryladenosine 3’,5’-cyclic 
monophosphate (cAMP; Sigma-Alddrich) to stimulate ATP-binding cassette transporter A1 
(ABCA1) expression. The next day, HDL (25 μg protein/ml) were added to the macrophages 
for the induction of cholesterol efflux. After 6 hours, an aliquot of medium was removed and 
centrifuged 5 minutes at 13’000 g to pellet cellular debris. The cholesterol [3H]-label in the 
supernatant was measured by liquid scintillation counting to quantitate the effluxed 
cholesterol. Meanwhile, the cells were incubated for at least 30 minutes with 0.1 M NaOH at 
room temperature, whereupon the radioactivity remaining within the cells was determined 
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by liquid scintillation counting of the cell lysates. Efflux per well was calculated as the 
percentage of counts released into the medium related to the total dose of radioactivity 
initially present (counts recovered within the medium added to the counts recovered from 
the cells). Values obtained from control cells without added HDLs were subtracted to correct 
for unspecific efflux. Values were normalized to values obtained with HDL isolated from a 






5.6.1. Healthy Control Plasma Samples 
Normolipidemic plasma samples from the blood bank in Zürich (Blutspende Zürich, Schlieren, 
Switzerland) were used for the isolation of HDL for the set-up of experimental conditions as 
well as the mechanistic experiments. Blood donors reported their health in a questionnaire. 
Lipaemic plasma samples were discarded.  
 
5.6.2. VIVIT Cohort 
Between September 1999 and October 2000, 750 Caucasian patients were enrolled in a long-
term study at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) in 
Feldkirch, Austria. There, the patients underwent coronary angiography for the evaluation of 
suspected or established coronary artery disease (CAD) 158. The study was approved by the 
Ethics Committee of the University of Innsbruck. All participants gave written informed 
consent. At baseline, anthropometric data were collected, clinical chemistry laboratory 
parameters were determined, and coronary angiography (Judkin’s technique) was performed 
on all study participants. Patients were categorized into subgroups without and with CAD 
(coronary artery stenosis with lumen narrowing of ≥ 50%), and with normal fasting glucose 
(NFG, <5.6 mmol/L), impaired fasting glucose (IFG, ≥ 5.6 and ≤ 6.9 mmol/L), and type 2 DM 
(>6.9 mmol/L), according to the WHO criteria. According to the criteria of the National 
Cholesterol Education Program Adult Treatment Panel III (ATPIII), metabolic syndrome in the 
patients was assigned if three or more of the following criteria were met: waist circumference 
>102 cm (♂) or >88 cm (♀), triglycerides ≥1.7 mmol/L, HDL-cholesterol <1.0 mmol/L (♂) or 
<1.3 mmol/L (♀), blood pressure ≥130/≥85 mmHg, and fasting glucose ≥6.1 mmol/L. 
 
1) Association of ApoC1 Content in HDL with Anti-Apoptotic Activity of HDL 
We received 30 plasma samples of patients from the VIVIT cohort with CAD, CAD and 
metabolic syndrome (CAD+MetS), and CAD and type 2 DM (CAD+T2DM) for our study of the 
association of the plasma donors’ glycemic state with anti-apoptotic activity and apoC1 











Age (years) 64.27 (±3.58) 63.83 (±4.15) 64.10 (±3.58) 0.5623 
Sex (male) 5 (50.00%) 5 (50.00%) 5 (50.00%) 1.0000 
Waist circumference (cm) 100.70 (±10.61) 102.40 (±10.01) 94.00 (±8.96) 0.1216 
Coronary artery stenosis >50% 10 (100.00%) 10 (100.00%) 10 (100.00%) n/a 
MetS ATP III Definition 8 (80.00%) 10 (100.00%) 0 (0.00%) <0.0001 
Type 2 DM (WHO) 10 (100.00%) 0 (0.00%) 0 (0.00%) <0.0001 
History of smoking 6 (60.00%) 4 (40.00%) 8 (80.00%) 0.1889 
BMI (kg/m2) 28.64 (±4.27) 28.49 (±1.86) 25.58 (±4.00) 0.1159 
Total cholesterol (mmol/L) 4.43 (±1.58) 5.30 (±1.58) 5.18 (±0.75) 0.2013 
HDL-cholesterol (mmol/L) 1.12 (±0.27) 1.26 (±0.33) 1.54 (±0.42)* 0.0271 
LDL-cholesterol (mmol/L) 2.92 (±1.47) 3.68 (±1.45) 3.36 (±0.57) 0.2132 
ApoA1 (g/L) 1.31 (±0.24) 1.47 (±0.23) 1.64 (±0.24)** 0.0104 
ApoB (g/L) 0.80 (±0.33) 0.95 (±0.28) 0.85 (±0.14) 0.3700 
Triglycerides (mmol/L) 1.73 (±0.70) 1.70 (±0.79) 1.36 (±0.55) 0.4213 
Fasting glucose (mmol/L) 7.49 (±2.44) 5.26 (±0.41)** 5.20 (±0.28)** <0.0001 
Glucose 120 min after GTT (mmol/L) 11.60 (±4.51) 6.32 (±1.93)** 6.34 (±1.14)** 0.0031 
HbA1c (%) 6.79 (±0.98) 5.67 (±0.25)*** 5.63 (±0.25)*** <0.0001 
C-reactive protein (mg/L) 7.18 (±7.91) 4.25 (±2.16) 2.52 (±1.65) 0.2357 
Antihypertensive drugs 9 (90.00%) 8 (80.00%) 9 (90.00%) 0.7494 
Statins 6 (60.00%) 4 (40.00%) 5 (50.00%) 0.6703 
Aspirin 8 (80.00%) 9 (90.00%) 9 (90.00%) 0.7494 
Table 5.3: Medical characteristics of coronary artery disease and type 2 diabetes mellitus 
(CAD+T2DM), CAD and metabolic syndrome (CAD+MetS), and CAD patients.  
Values are shown as mean ±SD for the continuous variables and as percentages for the categorical 
variables. For the continuous clinical variables, p-values were calculated using ANOVA followed by 
the Bonferroni’s post hoc test on the log transformed values. For the categorical variables, p-values 
were calculated using the 2 test.  
ATPIII: National Cholesterol Education Program Adult Treatment Panel III, BMI: Body mass index, 
Apo: apolipoprotein, GTT: glucose tolerance test (75 g oral glucose bolus), HbA1c: glycated 
hemoglobin, Antihypertensive drugs: beta-adrenergic blocking agents and/or angiotensin-converting-
enzyme inhibitors. 
* represents p<0.05 vs. T2DM, ** represents p<0.001 vs. T2DM, *** represents p<0.0001 vs. T2DM 
 
 2) Association of Apolipoprotein C1 with Incident Diabetes Mellitus  
For our study of apoC1 as prognostic marker for future type 2 DM development, 349 patients 
out of the above mentioned study VIVIT cohort were selected, for which eight years of follow-
up data existed. The 111 patients with type 2 DM at baseline were not used for our 
investigations, and 133 patients were excluded for incomplete follow-up data. The patient 
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characteristics of the investigated plasma donors (35 patients with and 70 patients without 
incident type 2 DM during the eight year follow-up period) are shown in table 5.4. 
 iT2DM (n=35) no iT2DM (n=70) p value 
Age (years) 64.49 (±10.31) 61.29 (±9.13) 0.1371 
Sex (female) 13 (37.14%) 26 (37.14%) 1.0000 
Hypertension (WHO) 21 (60.00%) 28 (40.00%) 0.0528 
History of smoking 16 (45.71%) 37 (52.86%) 0.4901 
Coronary artery stenosis >50% 23 (65.71%) 38 (54.29%) 0.2632 
MetS ATP III Definition 17 (48.57%) 15 (21.43%) 0.0044 
BMI (kg/m2) 27.14 (±5.13) 26.42 (±3.32) 0.5310 
Waist circumference (cm) 101.00 (±9.61) 99.79 (±6.66) 0.1666 
Waist-to-hip ratio 0.95 (±0.10) 0.93 (±0.09) 0.2567 
Total cholesterol (mmol/L) 5.80 (±1.30) 5.65 (±1.05) 0.7662 
HDL-cholesterol (mmol/L) 1.28 (±0.40) 1.31 (±0.39) 0.6927 
LDL-cholesterol (mmol/L) 3.44 (±0.89) 3.48 (±0.80) 0.6523 
Triglycerides (mmol/L) 2.20 (±1.62) 1.61 (±0.93) 0.0186 
Fasting glucose (mmol/L) 6.03 (±1.20) 5.76 (±1.06) 0.1858 
HbA1c (%) 6.01 (±0.55) 5.72 (±0.39) 0.0031 
Fasting insulin (pmol/L) 109.94 (±181.68) 62.37 (±31.98) 0.2212 
HOMA-IR 2.89 (±2.20) 2.28 (±1.25) 0.4800 
Systolic blood pressure (mmHg) 139.60 (±20.50) 131.60 (±19.09) 0.0510 
Diastolic blood pressure (mmHg) 79.85 (±13.62) 76.54 (±10.97) 0.2686 
C-reactive protein (mg/L) 7.84 (±14.86) 6.97 (±9.59) 0.7905 
Serum Potassium (mmol/L) 1.14 (±0.08) 1.10 (±0.10) 0.0284 
Creatinine (mol/L) 108.86 (±88.35) 93.10 (±13.11) 0.2264 
eGFR (CKD-EPI, mL/min per 1.73 m2) 67.19 (±18.07) 70.20 (±13.32) 0.1633 
Antihypertensive drugs 35 (100.00%) 57 (81.43%) 0.0065 
Lipid-lowering drugs 16 (45.71%) 37 (52.86%) 0.4901 
Aspirin 28 (80.00%) 54 (77.14%) 0.7386 
Table 5.4: Medical characteristics of plasma donors without (no iT2DM) and with incident type 2 
DM (iT2DM).  
Values are shown as mean ±SD for the continuous variables and as percentages for the categorical 
variables. For the continuous clinical variables, p-values were calculated using the two-sided 
Student’s t-test on the log transformed values. For the categorical variables, p-values were calculated 
using the 2 test.  
MetS: Metabolic Syndrome, ATPIII: National Cholesterol Education Program Adult Treatment Panel 
III, BMI: Body mass index, Apo: apolipoprotein, HbA1c: glycated hemoglobin, HOMA-IR: homeostatic 
model assessment-insulin resistance, eGFR: estimated glomerular filtration rate (calculated according 
to CKD-EPI formula 159), Antihypertensive drugs: beta-adrenergic blocking agents, angiotensin-
converting-enzyme inhibitors, angiotensin II receptor antagonists, calcium channel blockers, alpha 
blockers, thiazides, loop diuretics, potassium sparing diuretics, other diuretics, and/or other 














Age (years) 60.83 (±5.35) 60.95 (±5.35) 60.80 (±5.59) 60.83 (±5.66) 0.9998 
Sex (male) 15 (100.00%) 15 (100.00%) 14 (100.00%) 14 (100.00%) n/a 
Hypertension (WHO) 12 (80.00%) 13 (86.67%) 9 (64.29%) 11 (78.57%) 0.5332 
History of smoking 14 (93.33%) 12 (80.00%) 11 (78.57%) 10 (71.43%) 0.4969 
BMI (kg/m2) 28.80 (±5.05) 26.86 (±2.31) 27.01 (±4.93) 28.56 (±4.80) 0.5894 
Total cholesterol 
(mmol/L) 
5.18 (±0.77) 4.97 (±0.80) 6.06 (±1.19) 5.01 (±1.35) 0.0329 
HDL-C (mmol/L) 1.41 (±0.46) 1.63 (±0.49) 1.61 (±0.46) 1.23 (±0.32) 0.0632 
LDL-C (mmol/L) 3.31 (±0.77) 3.25 (±0.75) 4.02 (±1.04) 3.37 (±1.09) 0.1816 
ApoA1 (g/L) 1.53 (±0.30) 1.62 (±0.33) 1.60 (±0.24) 1.37 (±0.19) 0.0795 
ApoB (g/L) 0.92 (±0.22) 0.82 (±0.16) 0.98 (±0.24) 0.89 (±0.26) 0.3623 
Triglycerides (mmol/L) 1.98 (±1.08) 1.19 (±0.51) 1.87 (±1.11) 1.66 (±0.93) 0.1559 
Aspartate 
transaminase (IU/L) 
27.00 (±12.77) 32.20 (±22.91) 29.79 (±11.20) 29.29 (±8.20) 0.7420 
Alanine transaminase 
(IU/L) 





50.33 (±40.92) 42.86 (±29.51) 35.86 (±18.08) 0.1888 
Fasting glucose 
(mmol/L) 
9.42 (±2.95) 5.98 (±0.26)* 5.01 (±0.36)*§ 5.00 (±0.30)*§ <0.0001 
HbA1c (%) 7.83 (±1.41) 5.83 (±0.42)* 5.71 (±0.33)* 5.61 (±0.36)* <0.0001 
C-reactive protein 
(mg/L) 
3.28 (±2.61) 2.99 (±1.90) 5.74 (±9.93) 4.03 (±6.67) 0.9489 
Creatinine (mol/L) 77.20 (14.36) 79.56 (11.08) 75.14 (14.61) 84.61 (18.90) 0.4603 
eGFR (CKD-EPI, mL/min 
per 1.73 m2) 








31.31 (±31.03) 0.1656 
Antihypertensive drugs 9 (60.00%) 11 (73.33%) 8 (57.14%) 10 (71.43%) 0.7389 
Statins 7 (46.67%) 4 (40.00%) 6 (42.86%) 2 (14.29%) 0.2631 
Aspirin 9 (60.00%) 8 (53.33%) 10 (71.43%) 7 (50.00%) 0.6684 
Diabetes mellitus drugs 10 (66.67%) 0 (0.00%)* 0 (0.00%)* 0 (0.00%)* <0.0001 
Table 5.5: Medical characteristics of CAD+T2DM, CAD+IFG, CAD+NFG and no CAD+NFG subjects. 
Values are shown as mean ±SD for the continuous variables and as percentages for the categorical 
variables. For the continuous clinical variables, p-values were calculated using ANOVA followed by 
the Bonferroni’s post hoc test on the log transformed values. For the categorical variables, p-values 
were calculated using the 2 test.  
* represents p<0.0001 vs. T2DM, § represents p<0.05 vs. IFG 
BMI: Body mass index, HDL-C: High density lipoprotein cholesterol, LDL-C: Low density lipoprotein 
cholesterol, Apo: apolipoprotein, HbA1c: glycated hemoglobin, eGFR: estimated glomerular filtration 
rate (calculated according to CKD-EPI formula 159), Antihypertensive drugs: beta-adrenergic blocking 
agents, angiotensin-converting-enzyme inhibitors, and/or angiotensin II receptor antagonists; 




 3) Association of Glycemic State with Anti-Apoptotic Functionality of HDL  
We used 58 additional samples from the VIVIT cohort to investigate the association of the 
glycemic state with the anti-apoptotic functionality of HDL. To this end, we isolated HDL from 
type 2 DM patients with coronary artery disease (CAD+T2DM) and control groups (normal 
fasting glucose without coronary artery disease (no CAD+NFG), normal fasting glucose with 
coronary artery disease (CAD+NFG), and impaired fasting glucose with coronary artery disease 
(CAD+IFG)), The medical characteristics of the HDL donors of this study are shown in table 5.5. 
 
5.6.3. Functionality of HDL from Patients with Diabetes Mellitus Type 1  
We obtained plasma samples from 19 young, type 1 diabetic patients and 27 normoglycemic, 
age-matched control subjects. These samples had been collected in 2011 in the children and 
youth department of the Landeskrankenhaus in Feldkirch, Austria, at the supervision of Prof. 
Dr. Burkhard Simma. Dr. Anya Blassnig-Ezeh had been in charge for the patient recruitment 
and blood collection. All patients, or their parents, gave written informed consent. The 
subjects’ anthropometric data were collected, and clinical chemistry laboratory parameters 
were determined. The medical characteristics of the HDL donors (type 1 DM and control 




 T1DM (n=18) no T1DM (n=27) p value 
Age (years) 15.10 (±2.31) 14.93 (±2.30) 1.0000 
Sex (male) 10 (55.56%) 10 (37.04%) 0.2207 
BMI (kg/m2) 20.26 (±3.08) 21.69 (±5.18) 0.2549 
Total cholesterol (mmol/L) 4.30 (±0.90) 3.90 (±0.82) 0.1618 
HDL-cholesterol (mmol/L) 1.26 (±0.23) 1.04 (±0.30) 0.0055 
LDL-cholesterol (mmol/L) 2.59 (±0.86) 2.43 (±0.77) 0.6356 
nonHDL-cholesterol (mmol/L) 3.04 (±0.92) 2.88 (±0.84) 0.6088 
Cholesterol/HDL-Chol. ratio 3.50 (±0.93) 4.00 (±1.30) 0.2099 
ApoA1 (g/L) 1.59 (±0.24) 1.39 (±0.23) 0.0048 
ApoB (g/L) 0.76 (±0.22) 0.69 (±0.24) 0.3265 
Triglycerides (mmol/L) 1.00 (±0.41) 0.97 (±0.37) 0.8513 
Aspartate transaminase (IU/L) 23.59 (±3.81) 26.10 (±5.76) 0.1718 
Alanine transaminase (IU/L) 9.06 (±4.48) 6.75 (±2.80) 0.0162 
Fasting glucose (mmol/L) 12.18 (±4.62) 4.72 (±1.72) 0.0001 
HbA1c (%) 9.17 (±1.84) n/d n/a 
C-reactive protein (mg/L) 4.23 (±3.92) 3.62 (±5.79) 0.1651 
Creatinine (mol/L) 78.00 (±10.17) 72.71 (±11.10) 0.1303 
Insulin treatment 18 (100.00%) n/d n/a 
L-Thyroxin 5 (27.78%) n/d n/a 
Propanolol 1 (5.56%) n/d n/a 
Table 5.6: Medical characteristics of T1DM patients and control subjects (no T1DM) 
Values are shown as mean ±SD for the continuous variables and as percentages for the categorical 
variables. For the continuous clinical variables, p-values were calculated using the two-sided 
Student’s t-test on the log transformed values. For the categorical variables, p-values were calculated 
using the 2 test.  





5.7. Statistical Analyses 
Statistical analyses were done with the GraphPad Prism software version 5.00 (GraphPad 
software Inc., La Jolla CA, USA). Unless otherwise indicated, experiments were done at least 
in triplicates, and the bar graphs display the mean + one standard error of the mean (SEM) or 
standard deviation (SD). Scatter dot plots are shown with the median and interquartile ranges 
(IQR). Continuous patient variables were log-transformed before analysis. The Student’s t-test 
(two-sided) or analysis of variance (ANOVA) with Bonferroni’s post hoc test were used to test 
for significant differences between two or more groups, respectively. The 2 test was used to 
compare categorical patient variables. For correlation analyses of patient variables and 







6.1. Protective Effect of HDL against -Cell Apoptosis  
6.1.1. Effects of HDL and Interleukin-1 on -Cell Lines 
In a first step, we explored if IL-1 was capable to induce apoptosis in the pancreatic -cell 
lines INS-1E and Min6. Simultaneously, we investigated if HDL protected the cells from IL-1-
induced apoptosis. The increase in cytosolic DNA after apoptosis stimulation compared to a 
not treated condition was our indicator for apoptosis.  
In Min6 cells, stimulation of apoptosis with IL-1 for 48 hours was mild (1.5-fold) and the 
presence of HDL did not attenuate the induction of apoptosis (Fig. 6.1A). Thus, Min6 cells were 
ruled out as an unsuitable model for IL-1-induced apoptosis. In INS-1E cells, stimulation of 
apoptosis with IL-1 for 48 hours increased apoptosis by 2.5-fold compared to not treated 
cells, and HDL attenuated this induction (Fig. 6.1A).  
Further experiments with INS-1E cells confirmed that apoptosis was induced by IL-
1stimulation and prevented by HDL in a dose-dependent manner. INS-1E cells were 
incubated with different concentrations of HDL for 40 hours. The addition of IL-1 during the 
last 24 hours of the experiment revealed a preventive effect of HDL by 50% and more (Fig. 
6.1B). 16 hours of pre-incubation with HDL followed by 24 hours IL-1 stimulation in the 




Figure 6.1: Effect of HDL on IL-1-induced apoptosis in pancreatic -cells. 
A: INS-1E and Min6 cells were cultured for 48 hours in the presence or absence of HDL at a 
concentration of 20 g/ml, with and without IL-1 (10 ng/ml) for the stimulation of apoptosis. The 
white/grey bars indicate basal apoptosis, black bars IL-1-stimulated apoptosis (n=4).   
B: INS-1E cells were cultured for 40 hours in the absence or presence of HDL at the indicated 
concentrations. During the last 24 hours, IL-1 (10 ng/ml) was added for the stimulation of apoptosis 
(n=4).  
C: INS-1E cells were cultured for 16 hours in the absence (no HDL) or presence of 100 g/ml HDL 
(sequential and parallel). The medium was then replaced with medium containing either 10 ng/ml IL-
1 alone (no HDL and sequential) or both, 10 ng/ml IL-1 and 100 g/l HDL (parallel). Apoptosis 
induction was determined after 24 hours (n=4). 
Bars indicate the mean values +SEM; * represents p<0.05 compared to condition without HDL 
  
6.1.2. Effects of the HDL Components on Interleukin-1-Induced Apoptosis 
After verifying that HDL prevents IL-1-induced apoptosis in INS-1E cells, we analyzed the 
effects of both, the protein and the lipid moieties of HDL, as well as single components of HDL. 
Incubation with HDL and the protein moiety of HDL prevented apoptosis comparably and 
effectively (Fig. 6.2A). In contrast, the mild anti-apoptotic effect of the HDL lipid moiety was 





Figure 6.2: Effect of HDL components on IL-1-induced apoptosis. 
INS-1E cells were cultured in the presence of the indicated HDL components. During the last 24 
hours, IL-1 (10 ng/ml) was added for the stimulation of apoptosis.  
A: INS-1E cells were cultured for 40 hours in the presence or absence of HDL, the HDL protein moiety, 
the HDL lipid moiety (dissolved in ethanol (EtOH)), or EtOH alone at a concentration corresponding to 
50 g/ml HDL protein (n=8).   
B: INS-1E cells were cultured for 40 hours in the presence of the HDL protein moiety at the indicated 
concentrations (n=3).  
C: INS-1E cells were cultured for 40 hours in the presence of the 50 g/ml HDL protein moiety, heat 
denatured (h.d.) HDL protein moiety, or the trypsin digested and heat denatured (dig.) HDL protein 
moiety (n=1).  
D: INS-1E cells were cultured for 40 hours in the presence of apoA1 at the indicated concentrations 
(n=4).  
E: INS-1E cells were cultured for 40 hours in the presence of lipidated apoA1 (molar ratio 1:80 
apoA1:POPC) at the indicated concentrations (n=8 at 50 g/ml, n=2 at 100 g/ml).  
F: INS-1E cells were cultured for 40 hours in the presence of S1P at the indicated concentrations 
(n=3).  
Bars indicate the mean values +SEM; * represents p<0.05 compared to condition without HDL 
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The protective effect of the HDL protein moiety against IL-1-induced apoptosis was abolished 
by trypsin digestion of the protein moiety, whereas heat denaturation of the protein moiety, 
which was used for trypsin inactivation, did not affect the protective effect of the HDL protein 
moiety (Fig. 6.2C).  
The HDL protein moiety consists of about 100 different proteins including apolipoprotein A1 
(apoA1), which accounts for 70% of the protein mass. Moreover, apoA1 had previously been 
identified as an anti-apoptotic agent in -cells of human and murine islets 88. Therefore, we 
studied the effect of purified apoA1 in INS-1E cells. The purified apoA1 revealed no significant 
anti-apoptotic effect (Fig. 6.2D). This negative result was verified with several different apoA1 
preparations and over a broad range of concentrations. Lipidation of apoA1 with 1-palmitoyl-
2-oleoylphosphatidylcholine (POPC) in the molar ratio of 1:80 (apoA1:POPC) prior to the 
experiment neither revealed any anti-apoptotic effect for apoA1 (Fig. 6.2E).  
The HDL component sphingosine-1-phosphate (S1P) had previously been described to exert 
anti-apoptotic effects on many cells including -cells of human or murine islets 88. However, 
S1P did not prevent IL-1-induced apoptosis in INS-1E cells (Fig. 6.2F). 
 
6.1.3. Fractionation of HDL Protein Moiety 
Since apoA1 did not prevent IL-1-induced apoptosis in INS-1E cells, we sought to elucidate 
which protein(s) of the approximately 100 different proteins identified in HDL particles 
mediated the anti-apoptotic effect of HDL. For this purpose, the protein moiety was 
fractionated by liquid chromatography with an anion-exchange column. The fractions were 
pooled according to the peaks of the chromatogram into five pools (Fig. 6.3A). The different 
pools were initially analyzed by SDS-PAGE (Fig. 6.3B).  All pools contained apoA1 as their major 
protein component. We analyzed the five pools for their potential to prevent IL-1-induced 
apoptosis (Fig. 6.3C). Fractions B and D revealed both some potential to reduce IL-1-induced 
apoptosis. Fraction D contained a protein of about 30-35 kDa size, which is characteristic for 
apolipoprotein E (apoE) (asterisk in Fig. 6.3B), a protein regularly carried by HDL. However, 





Figure 6.3: Effect of HDL proteins on IL-1-induced apoptosis. 
A: Chromatogram of the anion-exchange chromatography of the HDL protein moiety with the pooled 
fractions indicated.  
B: 12% SDS-PAGE with different fraction pools after Coomassie-blue staining; * indicates a band at 
about 33 kDa.  
C: INS-1E cells were cultured for 40 hours in the presence of HDL, HDL protein moiety, or different 
pooled HPLC-fractions (A to E) at the indicated concentrations. During the last 24 hours, IL-1 (10 
ng/ml) was added for the stimulation of apoptosis (n=1 for pool A, B, C, E; n=2 for others).  
C: INS-1E cells were cultured for 40 hours in the presence of HDL, HDL protein moiety, or apoE at the 
indicated concentrations. During the last 24 hours, IL-1 (10 ng/ml) was added for the stimulation of 
apoptosis (n=1).  







6.1.4. Analysis of HDL Protein Fractions 
For further analysis of the protein moiety, we used the collaboration of our group with 
Meliana Riwanto from the Department of Cardiology 77 to analyze the proteome of the pooled 
HDL fractions A, B and D. As seen on the SDS-PAGE (Fig. 6.3B), apoA1 was the most abundant 
protein in all pools (Tab. 5.1). Pool D was characterized by the enrichment of apolipoprotein 
D (apoD) and apolipoprotein C1 (apoC1), which are otherwise little abundant proteins of HDL.  
 
Pool A Pool B Pool D 
Apolipoprotein 
Abundance 
rel. to apoA1 
Apolipoprotein 
Abundance 
rel. to apoA1 
Apolipoprotein 
Abundance 
rel. to apoA1 
ApoA1 100.00% ApoA1 100.00% ApoA1 100.00% 
ApoA2 4.32% ApoA2 36.10% ApoD 64.60% 
ApoD 0.63% ApoC2 6.62% ApoC1 46.20% 
ApoC3 0.56% ApoC3 1.80% ApoC3 6.46% 
ApoC2 0.53% ApoD 0.79% ApoM 6.46% 
ApoL1 0.15% ApoL1 0.51% ApoE 4.75% 
Table 6.1: Proteomic analysis of pooled HDL protein fractions. 
Analysis done by LC-ESI-MS/MS and quantified with internal standards. The abundance of proteins is 
expressed relative to apoA1. 
 
6.1.5. Effects of Apolipoprotein C1 and Apolipoprotein D 
Based on the proteome analysis, we tested if purified apoC1 or recombinant apoD protected 
the INS-1E cells from IL-1-induced apoptosis. At the same concentration, apoC1, but not 
apoD, prevented IL-1-induced apoptosis (Fig. 6.4A+B). For apoC1, the protective effect was 




Figure 6.4: Effect of apoC1 and apoD on IL-1-induced apoptosis. 
A+C: INS-1E cells were cultured for 40 hours in the presence of HDL, HDL protein moiety, or apoC1 at 
the indicated concentrations. During the last 24 hours, IL-1 (10 ng/ml) was added for the 
stimulation of apoptosis (n=6).  
B: INS-1E cells were cultured for 40 hours in the presence of HDL, HDL protein moiety, or apoD at the 
indicated concentrations. During the last 24 hours, IL-1 (10 ng/ml) was added for the stimulation of 
apoptosis (n=2).  
Bars indicate the mean values +SEM; * represents p<0.05 compared to condition without HDL 
 
6.1.6. Effect of Apolipoprotein C1-Deficient Murine HDL 
Motivated by the previous finding, we wondered about the protective effect of apoC1-
deficient HDL. In collaboration with P. Rensen and J. Berbée from Leiden (NL) 160, we obtained 
sera from human apoC1 transgene (apoC1Tg), apoC1 deficient (apoC1KO), and control mice 
to analyze their HDL for the potential to prevent IL-1-induced apoptosis. Overall, murine HDL 
revealed a lower anti-apoptotic effect than human HDL (Fig. 6.5). At a concentration of 50 
g/ml, at which human HDL elicit their maximal anti-apoptotic effect  
(-50%), HDL of wild type mice inhibited apoptosis by 20%, HDL of apoC1KO mice by 0%, and 
HDL of apoC1Tg mice by 30%. Of note, at a low concentration of 10 g/ml, where both human 
and murine HDL (wild type and apoC1Tg) inhibited apoptosis by 20%, HDL of apoC1KO mice 
had a rather pro-apoptotic effect.  
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Figure 6.5: Effect of HDL from mice with and without apoC1. 
INS-1E cells were cultured for 40 hours in the presence of different mouse HDL or human HDL at the 
indicated concentrations. During the last 24 hours, IL-1 (10 ng/ml) was added for the stimulation of 
apoptosis (n=1).  
Bars indicate the mean values +SD 
 
6.1.7. Association of Glycemic State with Anti-Apoptotic Activity and ApoC1 
Concentration of HDL 
Next, we investigated if the glycemic state of human plasma donors was associated with 
differences in HDL’s the anti-apoptotic activity on -cells and apoC1 content. Therefore, we 
isolated HDL from plasma samples of 10 patients with coronary artery disease and type 2 DM 
(CAD+T2DM HDL), 10 CAD patients with metabolic syndrome (CAD+MetS HDL) and 10 CAD 
patients without metabolic syndrome or diabetes (CAD HDL). The clinical details on the study 
subjects are listed in table 5.3 (see materials and methods section). According to their 
diagnosis, subjects differed fasting glucose levels (7.49 mM (CAD+T2DM) vs. 5.26 mM 
(CAD+MetS), and 5.20 mM (CAD), p<0.0001), glucose levels 120 minutes after a glucose 
tolerance test (11.60 mM (CAD+T2DM) vs. 6.32 mM (CAD+MetS), and 6.34 mM (CAD), 
p=0.0031), and glycated hemoglobin percentage (HbA1c, 6.79% (CAD+T2DM) vs. 5.67% 
(CAD+MetS), and 5.63% (CAD), p=0.0031)). Further differences with weaker statistical 
significance though were found in HDL cholesterol levels (1.12 mM (CAD+T2DM) vs. 1.26 mM 
(CAD+MetS), and 1.54 mM (CAD), p=0.0271), and apoA1 levels (1.31 g/L (CAD+T2DM) vs.  
1.47 g/L (CAD+MetS), and 1.64 g/L (CAD), p=0.0104). The other clinical variables were not 
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significantly different between the patient groups. HDL isolated from healthy blood donors 
obtained from the blood bank served as control (ctrl HDL).  
We did not observe any significant association of the HDL’s anti-apoptotic capacity with the 
glycemic state of the donor (Fig. 6.6A). The anti-apoptotic potential of HDL isolated from the 
different patients depict a high degree of inter-individual variation though.  
The apoC1 levels in HDL did not differ between the patient groups (Fig. 6.6B). However, a 
significant correlation between the apoC1 content of the HDL samples and their anti-apoptotic 
effect on INS-1E cells was observed (r=0.4151, Fig. 6.6C). Correlation analysis with the 
patient’s clinical variables revealed significant correlations of the HDL’s anti-apoptotic activity 
with triglyceride levels (r=0.5376) and HDL cholesterol (r=-0.3806, Fig. 6.6D+E, Tab. 6.2). 
























Figure 6.6: Protective effect of HDL is related to apoC1 content. 
A: INS-1E cells were cultured for 40 hours in the presence of 50 g/ml HDL from healthy control 
subjects (ctrl HDL, n=7) or patient donors with coronary artery disease and type 2 diabetes 
(CAD+T2DM, n=10), CAD and metabolic syndrome (CAD+MetS, n=10) or CAD (n=10). During the last 
24 hours, IL-1 (10 ng/ml) was added for the stimulation of apoptosis. 
B: ApoC1 content of the HDL samples described in 6A normalized to total HDL protein content.  
C: Correlation analysis of the data of the apoptosis experiments shown in 6A and the respective 
apoC1 content (relative to HDL protein content) shown in 6B. 
D+E: Correlation analysis of apoptosis reduction in -cells shown in 6A and triglyceride levels (D), or 
HDL-cholesterol levels (E) of the respective HDL donor.  
Scatter dot plots (A+B) are displayed with the median ± IQR. 








reduction of stim. apoptosis ApoC1 content 
Pearson r p value Pearson r p value 
Age 0.0237 0.9010 0.4867 0.0074 
Sex (male) -0.2104 0.2645 0.1366 0.4798 
History of smoking -0.1095 0.5645 0.1748 0.3646 
BMI 0.2449 0.1921 -0.0190 0.9221 
Waist circumference 0.2621 0.1618 0.1871 0.3311 
Triglycerides 0.5376 0.0022 0.2855 0.1333 
Total cholesterol 0.1257 0.5081 0.2298 0.2305 
LDL-cholesterol 0.1515 0.4242 0.1754 0.3627 
HDL-cholesterol -0.3806 0.0380 0.0163 0.9331 
ApoA1 -0.1274 0.5100 0.1132 0.5664 
ApoB 0.2308 0.2284 0.2186 0.2638 
Fasting glucose 0.3117 0.0936 0.0472 0.8080 
Glucose tolerance test (120min) -0.1773 0.3863 -0.1230 0.5581 
HbA1c 0.1140 0.5485 -0.1001 0.6055 
C-reactive protein 0.0832 0.6620 0.0157 0.9354 
Antihypertensive drugs 0.0191 0.9203 -0.0162 0.9334 
Statins 0.3513 0.0569 -0.0481 0.8043 
Aspirin 0.2601 0.1651 0.2200 0.2515 
Table 6.2: Correlation analysis between the patient’s clinical variables and the reduction of 
stimulated apoptosis by HDL, or the apoC1 concentration in HDL, respectively.  
The Pearson’s correlation coefficient r and p values (two-tailed test) are indicated.  
BMI: Body mass index, Apo: apolipoprotein, HbA1c: glycated hemoglobin, Antihypertensive drugs: 
beta-adrenergic blocking agents and/or angiotensin-converting-enzyme inhibitors. 
 
6.1.8. Association of Apolipoprotein C1 with Incident Diabetes Mellitus  
We investigated in a prospective study if apoC1 levels are associated with incident type 2 DM. 
ApoC1 levels were measured in total and apoB-depleted plasma (a surrogate for HDL) of 105 
patients of the VIVIT cohort who were normoglycemic at baseline. During eight years follow 
up, 35 persons out of the 105 had developed type 2 diabetes mellitus (Fig. 6.7A). The clinical 
variables of the study subjects are listed in table 5.4 (see materials and methods section). At 
baseline, the study subjects with incident type 2 DM differed from the study subjects without 
incident type 2 DM by significantly higher triglyceride levels (2.20 mM vs. 1.61 mM, p=0.0186), 
higher HbA1c levels (6.01% vs. 5.72%, p=0.0031), higher serum potassium levels (1.14 mM vs. 
1.10 mM, p=0.0284), as well as by higher prevalence of metabolic syndrome (48.57% vs. 
21.43%, p=0.0044), and antihypertensive drug treatment (100.00% vs 81.43%, p=0.0065). 
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Otherwise, the clinical variables were not significantly different between the subjects with and 
without incident type 2 DM.  
No differences in apoC1 plasma levels were found between persons developing type 2 
diabetes and persons not developing type 2 diabetes neither in the total plasma (Fig. 6.7B) 
samples nor in the apoB-depleted plasma (Fig. 6.7C). ApoC1 levels in both, total and apoB-
depleted plasma, correlated significantly with plasma levels of triglycerides (r=0.5117 / 
r=0.6207) and cholesterol (r=0.3598 / r=0.4792, Fig. 6.7D+E, Tab. 6.3). The waist 
circumference of the patients was correlated weakly with the apoC1 content of their plasma 
(r=0.2101, p=0.0432, Tab. 6.3). Moreover, patients with aspirin treatment, had slightly lower 
apoC1 levels in their plasma samples compared to patients without aspirin treatment  





Figure 6.7: Prospective study with apoC1 levels in future type 2 DM patients. 
A: Overview on study samples 
B: ApoC1 content of plasma samples from patients developing type 2 DM (iT2DM) and control 
subjects (no iT2DM) during the eight year follow up period 
C: ApoC1 content of apoB-depleted plasma samples (HDL-apoC1) from the same donors 
D-G: Correlation analysis of apoC1 content, or apoC1 content of apoB-depleted plasma samples 
(HDL-apoC1) shown in 7 B+C and triglyceride levels (D), total cholesterol levels (E). 
The regression line is shown for better visibility of the graph. 








ApoC1 content HDL-apoC1 content 
Pearson r p value Pearson r p value 
Age 0.0077 0.9381 0.0253 0.7979 
Sex (female) 0.1263 0.1993 0.1079 0.2735 
Hypertension (WHO) 0.0069 0.9447 -0.0737 0.4548 
History of smoking -0.0445 0.6522 -0.0652 0.5085 
Coronary artery stenosis >50% -0.0832 0.3988 -0.0158 0.8727 
MetS ATP III Definition 0.1224 0.2134 0.1662 0.0902 
BMI 0.0273 0.7836 -0.1147 0.2463 
Waist circumference 0.2101 0.0432 0.1998 0.0548 
Waist-to-hip ratio 0.0593 0.5723 0.0120 0.9092 
Triglycerides 0.5117 <0.0001 0.6207 <0.0001 
Total cholesterol 0.3598 0.0002 0.4792 <0.0001 
LDL-cholesterol 0.1365 0.1735 0.1661 0.0969 
HDL-cholesterol -0.0792 0.4286 -0.1023 0.3065 
Fasting glucose 0.0676 0.4935 0.0074 0.9402 
HbA1c -0.0017 0.9861 0.0714 0.4694 
Fasting insulin 0.1990 0.0533 0.0634 0.5415 
HOMA-IR 0.1706 0.1002 0.1403 0.1775 
Systolic blood pressure 0.1076 0.2793 0.0466 0.6401 
Diastolic blood pressure -0.0273 0.7850 -0.0814 0.4161 
C-reactive protein -0.0696 0.4917 -0.0300 0.7668 
Serum Potassium -0.0408 0.6883 0.0352 0.7295 
Creatinine -0.1601 0.1080 -0.1204 0.2281 
eGFR (CKD-EPI) 0.0371 0.7109 -0.0242 0.8095 
Antihypertensive drugs 0.1164 0.2369 0.0659 0.5043 
Lipid-lowering drugs 0.0209 0.8327 0.0506 0.6083 
Aspirin -0.2003 0.0405 -0.1905 0.0516 
Table 6.3: Correlation analysis between the patient’s clinical variables and the apoC1 concentration 
of the patient’s plasma, or the apoC1 concentration in the HDL fraction of the patient’s plasma, 
respectively.  
The Pearson’s correlation coefficient r and p values (two-tailed test) are indicated. 
MetS: Metabolic Syndrome, ATPIII: National Cholesterol Education Program Adult Treatment Panel 
III, BMI: Body mass index, Apo: apolipoprotein, HbA1c: glycated hemoglobin, HOMA-IR: homeostatic 
model assessment-insulin resistance, eGFR: estimated glomerular filtration rate (calculated according 
to CKD-EPI formula 159), Antihypertensive drugs: beta-adrenergic blocking agents, angiotensin-
converting-enzyme inhibitors, angiotensin II receptor antagonists, calcium channel blockers, alpha 
blockers, thiazides, loop diuretics, potassium sparing diuretics, other diuretics, and/or other 




6.2. Apoptotic Signaling Analysis 
We performed a genome-wide expression analysis at the Functional Genomics Center Zürich 
(FGCZ) to unravel the signaling cascades by which HDL inhibits IL-1-induced apoptosis of 
pancreatic -cells. For this purpose, the gene expression of INS-1E cells treated with and 
without IL-1 in the presence or absence of HDL was compared, and two different IL-1-
incubation times were analyzed: 24 hours and 12 hours (Fig. 6.8A). 
 
 
Figure 6.8: Gene expression analysis. 
A: Experimental set-up for gene expression analysis 
B: Cluster analysis of the 2000 probes with the highest standard deviation, threshold for standard 
deviation of log2 signal across samples: 0.504 
 
A cluster analysis of the 2000 genes with the highest variance revealed a massive effect of IL-
1 treatment on gene expression (Fig. 6.8B). Moreover, the two chosen incubation times 
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induced the formation of subclusters (red frames), although these differences were smaller. 
Unfortunately, the effect of HDL was minor or not consistent: The absence or presence of HDL 
did not induce the formation of clusters, neither with, nor without IL-1 stimulation.  
 
6.2.1. Effects of Interleukin-1 on Gene Transcription 
12 hours of IL-1 stimulation upregulated 1993 genes (log 2 ratio > 0.5), and downregulated 
1968 genes (log 2 ratio < -0.5) with a p-value < 0.05% and false discovery rate (FDR) < 0.1267 
(Fig. 6.9A). 24 hours of IL-1 stimulation upregulated 1392 genes (log 2 ratio > 0.5), and 
downregulated 1708 genes (log 2 ratio < -0.5) with a p-value < 0.05% and false discovery rate 
(FDR) < 0.1237 (Fig. 6.9B).  
Gene ontology analysis 156,157 of upregulated genes after 12 hours and 24 hours  
IL-1stimulation (orange dots in Fig. 6.9A+B) depicted functional annotation clusters related 
to immune and inflammatory responses, cell death, and the regulation of cytokine production 
(Tab. 6.4). The enrichment score is based on the p-values of the gene ontology terms within 
the respective cluster: a high enrichment score correlates with low p-values and vice versa. 
Gene ontology analysis of downregulated genes after 12 hours and 24 hours IL-1stimulation 

















12h IL-1 stimulated/not treated cells;  
upregulated genes 








Immune response 7.71 Immune response 9.88 
Translation 4.34 Inflammatory response 6.98 
Inflammatory response 4.02 Antigen processing and 
presentation 
4.97 
Nucleotide binding 3.87 Response to bacterium 4.23 
Response to bacterium 3.60 Cell death 4.04 
Protein dimerization activity 3.30 Lytic vacuole 3.93 
Induction of apoptosis 3.25 Regulation of cytokine 
production 
3.77 
Cell death 3.05 Cell activation 3.60 
Regulation of programmed cell 
death 
3.09 positive regulation of immune 
response 
3.31 
Regulation of cytokine 
production 
2.95 DEATH-like 3.04 
Response to organic substance 2.88 Cytokine activity 2.90 
Cation binding 2.76 Regulation of leukocyte 
migration 
2.86 
12h IL-1 stimulated/not treated cells;  
downregulated genes 








Chromosome 10.61 Endoplasmic reticulum 7.43 
Cell cycle 7.50 Cell fraction 4.80 
Cellular response to stress 5.81 Cytoplasmic vesicle 4.80 
Condensed chromosome 5.77 Regulation of secretion 4.78 
Non-membrane-bounded 
organelle 
5.55 Cell-cell signaling 4.00 
Membrane-enclosed lumen 5.38 Response to unfolded protein  3.49 





4.61 Protein dimerization activity 3.10 
Regulation of cell cycle 4.26 Cellular homeostasis 2.81 
Nucleotide binding 4.19 GTP-binding 2.78 
Protein dimerization activity 3.50 Nucleotide binding 2.65 
Response to hormone 
stimulus 
3.31 Sterol metabolic process 2.49 
Table 6.4: Annotation Clusters of up- or downregulated genes in response to 12 hours or 24 hours 





Figure 6.9: Expression data displayed in volcano plots. 
A-D: Each blue point represents the ratio of the expression data of the ratio of a single gene and the 
respective false discovery rate (FDR). Orange points represent the values which have log2 ratios of    
<-0.5 or >0.5 and p-values <0.05.  
A: Comparison of the gene expression of 12 hours IL-1-treated (10 ng/ml) cells (n=3) with not 
treated cells (n=3) 
B: Comparison of the gene expression of 24 hours IL-1-treated (10 ng/ml) cells (n=3) with not 
treated cells (n=2) 
C: Comparison of the gene expression of 30 hours HDL (50 g/ml) plus 12h IL-1-treated (10 ng/ml) 
cells (n=3) with 12 hours IL-1-treated (10 ng/ml) cells (n=3) 
D: Comparison of the gene expression of 40 hours HDL (50 g/ml) plus 24 hours IL-1-treated  
(10 ng/ml) cells (n=3) with 24 hours IL-1-treated (10 ng/ml) cells (n=3) 
 
6.2.2. Effects of HDL on Gene Transcription 
The absence or presence of HDL in addition to 12 h IL-1 stimulation led to differential 
expression of 456 genes (log 2 ratio > 0.5 or < -0.5, respectively) with a p-value < 0.05. 
However, the false discovery rate (FDR) of 0.5105 indicates more than 50% risk of false 
positives among these genes (Fig. 6.9C). The same comparison at 24 h IL-1 stimulation in the 
presence or absence of HDL disclosed 16 genes which were differentially regulated (log 2 ratio 
> 0.5 or < -0.5) with a p-value < 0.05 and a FDR < 0.7469 (Fig. 6.9D). The expression data of the 
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latter conditions (24 h IL-1 stimulation +/- HDL) were not investigated beyond this point, 
because of the high rate of false positives. 
Genes which were up- or downregulated by 12 h IL-1 stimulation and attenuated by the 
presence of HDL (orange dots in Fig. 6.9C) were used for functional annotation clustering 
analysis. (Tab. 6.5). These clusters include the regulation of transcription factors (NF-B 
among others), the endoplasmic reticulum stress response, protein biosynthesis, and the 
induction of apoptosis.  
Furthermore, functional annotation clustering analysis revealed that genes which were 
downregulated by 12 h IL-1 stimulation and attenuated by HDL, clustered with lipid 
biosynthetic processes, glucose metabolism, the response to hormone and cytokine stimuli, 
and cellular development.  
 
12h HDL+IL-1 stimulation/IL-1 stimulation;  
genes upregulated by IL-1, attenuated by HDL 
12h HDL+IL-1 stimulation/IL-1 stimulation;  







Cation binding 1.76 Lipid biosynthetic process 1.46 
Regulation of transcription 
factor activity 
1.53 SH3 domain 1.38 
Endoplasmic reticulum 
unfolded protein response 
1.44 Monosaccharide metabolic 
process 
1.36 
Intracellular organelle lumen 1.05 Phospholipid biosynthesis 1.35 
RNA processing 1.04 Response to hormone stimulus 1.15 
Regulation of transcription 1.02 Response to cytokine stimulus 1.11 
BTB/POZ fold 1.02 Nucleotide binding 0.97 
Leucine-rich repeat 0.99 DNA metabolic process 0.97 
Protein dimerization activity 0.98 DNA packaging 0.82 
Transport 0.96 Cellular homeostasis 0.81 
Transcription regulation 0.88 Regulation of hormone 
secretion 
0.77 
Positive regulation of 
apoptosis 
0.85 Regulation of cell development 0.73 
Table 6.5: Annotation Clusters of up- or downregulated genes in response to 12h IL-1 stimulation 
in the absence or presence of HDL.  
 
Given the relatively low enrichment scores (the enrichment score correlates inversely with the 
p-values of the gene ontology terms within the respective cluster) and high false discovery 
rates, though, these analyses must be interpreted with caution. Nevertheless, we decided to 




6.2.3. Validation of Candidate Genes with Quantitative PCR 
We selected several genes for validation out of the apoptotic pathways, which had been 
differentially regulated by IL-1 and HDL in the gene array (red circles in Fig. 6.10). These genes 
were located in the ER stress pathway, in the intrinsic or extrinsic apoptotic pathway. 
Additional time points were analyzed to better resolve the effects of IL-1 and HDL for 
quantitative real-time PCR (qPCR) analyses. Thus, we used RNA samples which were collected 
in two independent experiments from cells either exposed to IL-1 for 8, 12 and 16 hours, or 
3, 6, 10, 16 and 24 hours, in the presence or absence of HDL. Gene expression changes and 
the time of the maximal fold change are listed in table 6.6. Similarly to the results of the gene 
array, the validation experiments revealed major effects of IL-1 treatment in the 
transcription of the tested genes when compared to not treated cells (left side of table 6.6). 
The presence of HDL in addition to IL-1 treatment only induced a minor attenuation of up- 
or downregulation of these genes (right side of table 6.6).  
 
Figure 6.10: Network of genes, transcription factors, enzymes, and signalling molecules involved in 
-cell apoptosis.  





 IL-1treated vs. not treated cells IL-1 + HDL treated vs. not treated cells 
Gene Fold change peak at Fold change peak at 
DP5 6.3x 10-12h 6.5x 10-12h 
Bcl-xL 1.6x 10h 1.6x 10h 
BIM 0.3x 6-8h 0.4x 6-8h 
STAT1 3.3x 8+16h 3.3x 8+16h 
IL-1R 1.8x/1.9x 3+24h 2.2x/1.6x 3+24h 
CHOP 7.4x 10-12h 5.6x 10-12h 
sXBP1 1.9x/1.8x 3+16h 2.3x/1.6x 3+16h 
ATF6 3.5x 16h 3.4x 16h 
CFLAR/FLIP 2.2x 6h 2.1x 3h 
FAS 26.8x 3h 32.6x 3h 
Table 6.6: Fold changes of gene expression in response to IL-1 or IL-1 + HDL treatment compared 
to not treated cells, including time of maximal up- or downregulation of the gene.  
DP5: death protein 5; B-cell lymphoma extra Large; Bim: Bcl-2-like protein 11; STAT1: signal 
transducer and activator of transcription 1; IL-1R: Interleukin 1 receptor; CHOP: C/EBP homologous 
protein; sXBP1: spliced X-box binding Protein 1; ATF6: activating transcription factor 6; CFLAR/FLIP: 
CASP8 and FADD-like apoptosis regulator / FLICE-like inhibitory protein 
 
6.2.4. Translocation of Transcription Factor NF-B 
Several of the differentially expressed genes, which were found in the gene array, are linked 
to the transcription factor NF-B, which is related to cell survival (Fig. 6.11). Therefore, the 
involvement of NF-B was analyzed by studying the subcellular location of its subunit p65 by 
fluorescence microscopy. INS-1E cells were treated with IL-1 for different times in the 
absence or presence of HDL. After fixing and staining, the inspection at the microscope 
revealed a drastic translocation of NF-B into the nucleus after 15 and 60 minutes of IL-1 
treatment (Fig. 6.11). Interestingly, at 5 minutes stimulation with IL-1, NF-B was still in the 
cytoplasm, and after 5 h the NF-B was relocated back into the cytoplasm. The presence of 





Figure 6.11: Effect of IL-1 on the translocation of p65 NF-B into the nucleus. 
Location of the p65 subunit of NF-B (pink) after the indicated stimulation time with IL-1 (10 ng/ml) 
in the absence or presence of HDL (100 g/ml), blue=DAPI. 
 
6.2.5. Involvement of ER Stress  
IL-1 had been found to upregulate several genes involved in ER stress (Fig. 6.11) which, 
according to the gene array, was partially prevented by the presence of HDL. Therefore, we 
sought to confirm this link between HDL and ER-stress, and started a collaboration with 
Christian Widmann’s group in Lausanne. This group had published that HDL prevents 
apoptosis and ER stress in primary human -cells as well as in Min6 cells induced by 
thapsigargin, a drug which inhibits the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) 
109,111. Christian Widmann, a member of my PhD committee, invited me to join his group for a 
few experiments.  
We investigated if apoC1 mimicked the protective effect of HDL against ER stress-induced 
apoptosis in Min6 cells. The cells were treated with HDL or apoC1, and thapsigargin (ThG) for 
24 h. The expression of CHOP (a marker of ER stress) was consistently upregulated by ThG 
treatment and blocked by HDL, but unfortunately not by apoC1 (Fig. 6.12A). For the 
phosphorylation of PERK, the data were not as clear. PERK phosphorylation was induced by 
ThG, as expected. In the presence of either HDL or apoC1 the effect of ThG was attenuated, 
however, to a lesser degree by apoC1 as compared to HDL. Finally, the number of pycnotic 
nuclei revealed clearly less apoptosis after ThG treatment in the presence of either 1mM  




Figure 6.12: Effect of HDL or apoC1 on thapsigargin-induced ER stress. 
A-C: Min6 cells were cultured for 24 hours with or without thapsigargin (0.5 M, dark grey bars) in 
the presence or absence of HDL (two preparations) or apoC1 at indicated concentrations.  
A:  RNA was harvested after 24 h of treatment and the gene expression levels of CHOP were 
determined by qPCR 
B: Proteins were harvested after 24 h of treatment and the phosphorylation of PERK (170 kDa) was 
analyzed using specific antibodies. Tubulin (55 kDa) was used as loading control. The graph displays 
the averaged quantification of three western blots. The numbers within the bars correspond to the 
columns in the western blot.   
C: After the treatment, Min6 cells were fixed with PFA and the nuclei were stained with Hoechst 
stain. The pychnotic nuclei were counted carefully (at least 500 cells per condition in triplicates).  
D: INS-1E cells were cultured for 40 hours in the presence of HDL or apoC1 at indicated 
concentrations. During the last 16 hours, thapsigargin (25 nM, dark grey bars) was added in order to 
induce apoptosis.  
Bars indicate the mean values +SD 
 
To further investigate the role of apoC1 in ER stress-induced apoptosis, the experiments were 
rerun in INS-1E cells. ThG-induced apoptosis in INS-1E cells, and the ThG-induced apoptosis 
was reduced by HDL but not by apoC1 at either of the tested concentrations (5 g/ml and  
20 g/ml) (Fig. 6.12D). Compared to Min6 cells, the concentration optimum of ThG to induce 
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apoptosis was twenty times lower in INS-1E cells (0.5 M in Min6 cells vs. 25 nM in INS-1E 
cells). Likewise, the HDL concentration which prevented ThG-induced apoptosis was about ten 
times lower in INS-1E cells (1 mM HDL-cholesterol in Min6 cells vs. 100 g/ml HDL-protein in 
INS-1E cells).  
Thapsigargin-induced apoptosis was found with two additional assays: annexin V / propidium 
iodide staining (Fig. 6.13B+C) and caspase 3 activation (Fig. 6.13D+E). Since apoC1 was not 
preventing ThG-induced apoptosis, we could not exploit this model to delineate the 





Figure 6.13: Alternative methods for apoptosis detection after stimulation with thapsigargin. 
A: INS-1E cells were cultured for 40 hours in the presence or absence of HDL. Thapsigargin (ThG,  
50 nM, grey bars) was added for the stimulation of apoptosis during the last 16 hours. Apoptosis was 
determined with the cell death detection ELISA (n=1). 
B+C: INS-1E cells were cultured for 40 hours in the presence or absence of HDL (100 g/ml) or apoC1 
(50 g/ml). Thapsigargin (ThG, 50 nM) was added for the stimulation of apoptosis during the last 16 
hours.  
B: Scatterplot of flow cytometry with annexin V- versus Propidium iodine (PI)-staining (n=1).  
C: Average percentage of early apoptotic (annexin V positive, PI negative, grey) and late apoptotic 
(annexin V and PI positive, blue) cells (n=1). 
D+E: INS-1E cells were cultured for 40 (D) or 24 (E) hours in the absence or presence of HDL at the 
indicated concentrations. During the last 16 (D) or 8 (E) hours, ThG (50 nM) was added for the 
stimulation of apoptosis except in the not treated control (Ctrl) condition.  
D: Cleaved caspase 3 (17 kDa) was detected in proteins which were harvested from INS-1E cells.  
E: Apoptosis was determined by the caspase 3 activity assay (n=1). 
Bars indicate the mean values +SD 
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6.3. Clinical Studies on the Impact of Diabetes on HDL Functionality 
To investigate further components of HDL, which might interfere with ThG-induced apoptosis, 
we used an approach, which our lab previously applied in collaboration with the group of Ulf 
Landmesser (Department of Cardiology) for the identification of HDL-components, which 
protect endothelial cells from apoptosis. In that study 77, HDL of coronary artery disease 
patients and healthy controls differed by anti-apoptotic activity, functional parameters of 
endothelial cells (i.e. the stimulation of nitric oxide (NO) production and the inhibition of 
stimulated VCAM-1 expression), and protein composition. For -cells, no comparable study 
had been done. Therefore, we measured effects of HDL from healthy and diabetic adolescent 
and adult study subjects on the survival of -cells. We also analyzed the cholesterol efflux 
capacity of HDL isolated from the adolescents, because HDL can elicit cellular responses by 
altering the cellular cholesterol homeostasis. 
The detailed clinical variables of the study subjects are listed in tables 5.5 and 5.6 (see 
materials and methods section). The adolescents with type 1 DM differed from the age-
matched control subjects by significantly higher fasting glucose levels (12.18 mM vs. 4.72 mM, 
p=0.0001) (Tab. 5.6), alanine transaminase (ALT) activity (9.06 IU/L vs. 6.75 IU/L, p=0.0162), 
HDL cholesterol (1.26 mM vs. 1.04 mM, p=0.0055), and apoA1 levels (1.59 g/L vs. 1.39 g/L, 
p=0.0048). Otherwise, the clinical variables were not significantly different between the  
type 1 DM subjects and control subjects.  
By definition, the adult patients with coronary artery disease and type 2 DM (CAD+T2DM), 
impaired fasting glucose (CAD+IFG) and euglycemia (CAD+NFG and no CAD+NFG)) differed by 
fasting glucose (p<0.0001), HbA1c (p<0.0001), and treatment for type 2 DM (p<0.0001) (Tab. 
5.5). Moreover, total cholesterol levels differed slightly between the groups (p=0.0329): 
subjects with normal fasting glucose and coronary artery disease (CAD+NFG) had the highest 
cholesterol levels (6.06 mM vs. 5.18 mM (CAD+T2DM), 4.97 mM (CAD+IFG), and 5.01 mM  






6.3.1. Protective Effects in -Cells 
Apoptosis of INS-1E cells was stimulated by ThG-treatment. Activated caspase 3 was measured 
as a surrogate for apoptosis in this study. HDL from type 1 diabetic adolescents had slightly 
less anti-apoptotic potential on INS-1E cells than HDL from healthy adolescents (p=0.3535, Fig. 
6.14A). However, this difference was not significant. Neither was the glycemic state of adult 
patients associated with any significant differences of their HDLs’ anti-apoptotic activity (Fig. 
6.14B).  
 
Figure 6.14: Anti-apoptotic effects of HDL from type 1 and type 2 DM patients. 
A: INS-1E cells were cultured for 24 hours in the presence of HDL samples (100 g/ml) collected from 
type 1 DM adolescents (T1DM HDL, n=19) or healthy, age-matched adolescents (no T1DM HDL, 
n=27). During the last 8 hours, ThG (50 nM) was added for the stimulation of apoptosis. Apoptosis 
was determined by the caspase 3 activity assay. The apoptosis reduction of the internal control HDL 
compared with ThG-stimulated apoptosis without HDL was set as 100% apoptosis reduction.  
B: INS-1E cells were treated as described in A. HDL samples were isolated from patients with type 2 
DM and coronary artery disease or impaired fasting glucose and CAD (CAD+T2DM or CAD+IFG HDL, 
respectively, n=15 each), or euglycemic subjects with or without CAD (CAD+NFG HDL or no CAD+NFG 
HDL, respectively, n=14 each). 
Scatter dot plots are displayed with median values ±IQR 
 
6.3.2. Cholesterol Efflux from Macrophages 
HDL isolated from patients with type 1 DM differed from HDL of control subjects by a slightly 
reduced potential to induce cholesterol efflux from J774 macrophages, which had previously 
been loaded with acetylated LDL and cholesterol (Fig. 6.15A+B). However, neither for the 
macrophages, in which ABCA1 expression had been stimulated with cyclic adenosine 
monophosphate (cAMP, Fig. 6.15B), nor for the macrophages without cAMP stimulation (Fig. 




Figure 6.15: Functionality of HDL from type 1 and type 2 DM patients towards macrophages. 
A+B: J774 macrophage cells were loaded with cholesterol for 24 hours, followed by the induction of 
ABCA1 expression with cAMP (B) or not (A). Cholesterol efflux induced by HDL from subjects with or 
without type 1 DM (25 μg/ml) is shown as % of the internal control HDL.  
Scatter dot plots are displayed with median values ±IQR. 
 
6.3.3. Correlation Analysis between Functionality of HDL and the Clinical Variables 
of Study Participants 
Correlation analysis between the functionality of HDL towards -cells and macrophages, and 
the clinical variables of the study subjects with type 1 DM and control subjects revealed 
significant, negative correlations of the potential of HDL to reduce thapsigargin-stimulated 
apoptosis with LDL cholesterol levels (r=-0.3204), non-HDL cholesterol levels (r=-0.3066), the 
cholesterol-to-HDL cholesterol ratio (r=-0.3131), and apoB levels (r=-0.2963, Tab. 6.7). 
Moreover, the potential of HDL to induce cholesterol efflux from macrophages without ABCA1 
expression stimulation by cyclic adenosine monophosphate (cAMP) was positively correlated 
to total cholesterol levels (r=0.3922), LDL cholesterol levels (r=0.3554), non-HDL cholesterol 
levels (r=0.3244) and the activity of aspartate transaminase (r=0.3573) in the subjects with 
type 1 DM (Tab. 6.7). When the ABCA1 expression was stimulated by 24 hours of incubation 
with medium containing cAMP, cholesterol efflux from macrophages correlated positively 
with the total cholesterol levels (r=0.3411) and apoB concentrations (r=0.3663) of the plasma 
donors (Tab. 6.7). As expected, a positive correlation was found between the HDL-induced 
cholesterol efflux from macrophages with and without prior incubation with cyclic adenosine 
monophosphate (r=0.6409, Tab. 6.8). The other functionality tests for HDL or patient variables 




reduction in -cells 
Cholesterol efflux 
without cAMP from 
macrophages 
Cholesterol efflux 
with cAMP from 
macrophages 
Clinical variables r p value r p value r p value 
Age -0.1211 0.4334 -0.2639 0.0834 -0.1313 0.3957 
Sex (male) 0.1855 0.2225 -0.1777 0.2429 -0.0980 0.5219 
BMI -0.1963 0.2247 0.0682 0.6759 0.1391 0.3921 
Total cholesterol -0.2469 0.1149 0.3922 0.0102 0.3411 0.0271 
HDL-cholesterol 0.1887 0.2313 0.1865 0.2370 0.1812 0.2508 
LDL-cholesterol -0.3204 0.0386 0.3554 0.0209 0.2702 0.0835 
nonHDL-cholesterol -0.3066 0.0483 0.3244 0.0361 0.2754 0.0775 
Cholesterol/HDL-chol. ratio -0.3131 0.0435 0.1265 0.4248 0.1103 0.4869 
ApoA1 0.1300 0.3948 0.2680 0.0751 0.2015 0.1844 
ApoB -0.2963 0.0481 0.2744 0.0682 0.3663 0.0133 
Triglycerides -0.0948 0.5503 0.0006 0.9971 0.1594 0.3134 
Aspartate transaminase 0.1463 0.3808 0.3573 0.0277 0.2530 0.1253 
Alanine transaminase 0.0100 0.9497 -0.0164 0.9181 0.0465 0.7700 
Fasting glucose 0.0605 0.7037 -0.0384 0.8095 0.1183 0.4555 
HbA1c -0.0611 0.8158 -0.2457 0.3417 -0.0649 0.8044 
C-reactive protein 0.0436 0.7838 0.0473 0.7662 0.0912 0.5655 
Table 6.7: Correlation analysis in T1DM patients and control subjects between the patient’s clinical 
variables, and the HDL functionality data % apoptosis reduction of control HDL in -cells, or 
cholesterol efflux with and without cAMP from macrophages. 
The Pearson’s correlation coefficient r and p values (two-tailed test) are indicated.  
cAMP: cyclic adenosine monophosphate, BMI: body mass index, Apo: apolipoprotein, HbA1c: 
glycated hemoglobin.  
 
 
   
apoptosis reduction in -cells 
Cholesterol efflux without 
cAMP from macrophages    
Cholesterol efflux with 
cAMP from macrophages  
Pearson r -0.0998 0.6409 
p value 0.5144 <0.0001 
Cholesterol efflux without 
cAMP from macrophages 
Pearson r -0.0586  
p value 0.7024  
Table 6.8: Correlation analysis in T1DM patients and control subjects between HDL functionality 
data % apoptosis reduction of control HDL in -cells and cholesterol efflux (expressed as % of 
control HDL) from macrophages with and without prior cyclic adenosine monophosphate (cAMP) 
stimulation.  






Correlation analysis of the functionality of type 2 DM patients’ and their controls’ HDL with 
their clinical variables revealed a positive and significant correlation between the ability of 
these HDL to reduce thapsigargin-stimulated apoptosis and HDL cholesterol (r=0.2772) as well 
as apoA1 levels (r=0.3173, Tab. 6.9). Otherwise, none of the tested variables correlated with 
the potential of the patient’s HDL to reduce ThG-stimulated apoptosis in INS-1E cells.  
 
 apoptosis reduction in -cells 
Clinical variables Pearson r p value 
Age 0.1980 0.1362 
Sex (male) n/a n/a 
Hypertension (WHO) 0.0529 0.6934 
History of smoking 0.0770 0.5659 
BMI 0.0553 0.6802 
Total cholesterol 0.1513 0.2571 
HDL-Cholesterol 0.2772 0.0351 
LDL-Cholesterol 0.0832 0.5345 
ApoA1 0.3173 0.0152 
ApoB 0.0607 0.6510 
Triglycerides 0.0115 0.9316 
Aspartate transaminase 0.0627 0.6400 
Alanine transaminase 0.0006 0.9967 
Gamma-glutamyl transferase 0.0339 0.8008 
Fasting glucose 0.1283 0.3372 
HbA1c 0.0452 0.7362 
C-reactive protein -0.2095 0.1145 
Creatinine -0.1051 0.4325 
eGFR (CKD-EPI) 0.0381 0.7762 
Albumin creatinine ratio 0.0867 0.5897 
Antihypertensive drugs -0.0172 0.8979 
Statins -0.1789 0.1791 
Aspirin -0.2229 0.0926 
Diabetes mellitus drugs 0.0463 0.7298 
Table 6.9: Correlation analysis in T2DM, CAD, CAD+IFG patients and control subjects between the 
patient’s clinical variables, and the HDL functionality data % apoptosis reduction of control HDL in 
-cells. 
The Pearson’s correlation coefficient r and p values (two-tailed test) are indicated. 
BMI: Body mass index, Apo: apolipoprotein, HbA1c: glycated hemoglobin, eGFR: estimated 
glomerular filtration rate (calculated according to CKD-EPI formula 159), Antihypertensive drugs: beta-
adrenergic blocking agents, angiotensin-converting-enzyme inhibitors, and/or angiotensin II receptor 






7.1. Protective Effect of HDL against -Cell Apoptosis  
Type 2 DM has been misunderstood as a disease of insulin resistance for some time. However, 
during the last two decades it has been established that insulin resistance is not sufficient for 
the manifestation of type 2 DM 15,16,26. The transition from normal glucose tolerance to 
impaired glucose tolerance and finally type 2 DM is driven by the cumulative loss of -cell 
function and mass in the background of peripheral insulin resistance 20,27. 
Tissue inflammation, which is often found in patients with metabolic diseases, is likely to 
induce -cell apoptosis 56. The human lipoproteins HDL, LDL, and VLDL are possible modulators 
of -cell function and survival 107. In this context, the precursor PhD project of this thesis 
investigated the influence of HDL and LDL on -cell apoptosis, proliferation and function in 
primary pancreatic islets of human and murine origin 88. These studies found a protective 
effect of HDL against high glucose- and IL-1-induced apoptosis. The anti-apoptotic effects 
were found to be exerted by both, the protein and lipid moieties of HDL, as well as by isolated 
apoA1 and S1P. 
The goal of the follow-up project, which is presented here, was to elucidate the mechanism 
underlying the protective effects of HDL and its components in -cells. Since we were 
specifically interested in effects which happen in the -cells we chose to work with a -cell 
line. With IL-1-induced apoptosis in INS-1E cells (Fig.6.1A), we established a suitable model 
to study the protective effects of HDL and its components.  
 
7.1.1. Protective Effects of HDL and its Components  
The physiological HDL concentration in human plasma ranges between 1 and 2 mmol/l 
cholesterol. This is equivalent to 1 to 2 mg/ml total protein. Since the vasculature of pancreatic 
islets is fenestrated, the concentration of HDL around -cells in vivo presumably lies in the 
range of the HDL plasma concentration 91. Interestingly, the anti-apoptotic effect of HDL 
started to become relevant at a protein concentration as low as 20 g/ml in our experiments 
with IL-1-induced apoptosis (Fig 6.1B). This corresponds to maximally 2% of the normal 
plasma concentration.  
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HDL is a good scavenger for amphiphilic molecules, e.g. lipopolysaccharide 161. Therefore, we 
investigated if HDL simply neutralizes IL-1 when it prevents apoptosis. For this purpose,  
INS-1E cells were pre-incubated with HDL followed by IL-1 stimulation in the absence of HDL 
(Fig 6.1C). The significant anti-apoptotic effect that was detected indicates that HDL did not 
scavenge the cytokine, but rather activated a sustained, protective program in the -cells.  
A profound and dose-dependent protective effect was found for the HDL protein moiety in 
the INS-1E -cell line (Fig 6.2A+B). Interestingly, this effect was abolished when the HDL 
protein moiety was digested with trypsin before the incubation with the INS-1E cells (Fig 6.2C).  
In contrast to our previous findings in murine and human islets 88, we found protective effects 
of neither apoA1 nor S1P in INS-1E cells (Fig 6.2D-F). It cannot be excluded that these 
molecules had induced indirect protective effects on -cells within the pancreatic islets in 
those experiments, i.e. by interaction with non- cells. Moreover, recent work has claimed 
that S1P is only able to exert anti-inflammatory effects on endothelial cells once it is bound to 
apoM 162,163. It is well possible that complexing with albumin as done by us (but also other 
laboratories) did not allow S1P to inhibit the IL-1-induced apoptosis of INS-1E cells. However, 
the loss of protective HDL effects on INS-1E cells upon digestion of HDL proteins indicate that 
HDL protein(s) other than apoA1 specifically protect -cells from IL-1-induced apoptosis. 
In order to identify candidate proteins among the more than 100 proteins found in HDL 67, the 
protein moiety was fractionated by liquid chromatography with an anion-exchange column 
(Fig 6.3A+B). Five pools of fractions revealed different anti-apoptotic features (Fig 6.3C). Since 
we could not identify single proteins with this technique, we used the collaboration of our 
group with Meliana Riwanto from the Department of Cardiology to analyze the proteome of 
three protective HDL fractions with LC-ESI-MS/MS 77. The apolipoproteins apoC1 and apoD 
were found to be enriched in the most anti-apoptotic pool (pool D) compared to the regular 
HDL protein composition (Tab 6.1). Further analyses of these two proteins revealed a 
significant and dose-dependent anti-apoptotic effect for apoC1 in -cells when apoptosis was 
stimulated with IL-1(Fig 6.4A-C). Thus, apoC1 was selected for more detailed follow-up 




7.1.2. Effects of Apolipoprotein C1 on -Cells 
Several interesting functions of apoC1 have been described – beneficial and adverse. ApoC1 
activates LCAT and inhibits CETP as well as hepatic lipase 80–82. Moreover, apoC1 inhibits the 
selective uptake of cholesteryl esters from HDL into hepatocytes mediated by SR-BI 82. The 
combination of these apoC1 functions increases HDL stability. Otherwise, apoC1 was reported 
to increase VLDL levels. It reduces lipoprotein lipase activity as well as apoE-mediated binding 
to the LDL receptor or the LDL receptor related protein by inducing conformational changes 
of VLDL and chylomicrons 80,164. Interesting findings arose from apoC1 transgenic and apoC1-
deficient mice: ApoC1 transgenic (apoC1Tg) mice in an ob/ob background were reported to 
be protected from obesity and impaired glucose tolerance 160. Moreover, apoC1 deficient mice 
displayed elevated CE and TG content in the liver, as well as decreased plasma levels of  
HDL 165. 
The published information on apoC1 effects together with our previous finding (Fig 6.4) 
motivated us to investigate the role of apoC1 in HDL in the context of -cell apoptosis. For this 
purpose, we received sera from human apoC1 transgene (apoC1Tg), apoC1 deficient 
(apoC1KO) and control mice from P. Rensen and J. Berbée (Leiden, NL). Unfortunately, the 
results were equivocal and the limited amount of available mouse sera impeded any 
replication of the experiment. The anti-apoptotic effect of murine (WT) HDL on -cells was 
considerably weaker (-20% for 50 g/ml; Fig 6.5) than the anti-apoptotic effect of human HDL 
(-50% for 50 g/ml) which limits the comparability to human HDL. Furthermore, at a low 
concentration of 10 g/ml HDL of apoC1KO mice elicited a rather pro-apoptotic effect that 
disappeared at higher concentrations. Thus, our hypothesis that apoC1 acts as a potent anti-
apoptotic protein in HDL was neither rejected nor supported by our analysis of HDL from 
genetic mouse models.  
 
7.1.3. Clinical Studies on the Associations between ApoC1, Anti-Apoptotic Activity 
and Glycemic State  
Since the results with murine HDL were not conclusive, we sought to investigate the anti-
apoptotic activity of apoC1 towards -cells in human HDL. Humans with an apoC1-deficiency 
are not known. However, it had been reported that the apoC1 concentration in HDL of patients 
with diabetes mellitus was lower compared to HDL of healthy subjects 93. We therefore 
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compared HDL from coronary artery disease (CAD) patients differing by the presence or 
absence of metabolic syndrome or type 2 DM towards their anti-apoptotic potential on IL-1 
stimulated INS-1E cells and their apoC1 content. Unfortunately, neither the anti-apoptotic 
capacity nor the apoC1 content of the tested HDL was associated with the glycemic state of 
the plasma donors (Fig 6.6A+B). However, we found a significant correlation between the 
apoC1 content of the HDL samples and their anti-apoptotic effect on INS-1E irrespective of the 
glycemic state of the plasma donors (Fig 6.6C).  
-cell apoptosis is particularly relevant during the manifestation of type 2 DM. We therefore 
hypothesized that – if apoC1 had anti-apoptotic properties on -cells – individuals with low 
levels of apoC1 would be predisposed to develop type 2 DM. In a prospective study of CAD 
patients, we investigated whether baseline apoC1 levels are associated with incident type 2 
DM. During eight years follow up, 35 persons out of our 105 patients who were 
normoglycemic at the baseline examination, developed type 2 DM (Fig 6.7A). In this cohort 
our lab previously identified atypical sphingolipids and some circulating microRNAs as 
biomarkers of incident diabetes 166,167. However, no differences in baseline apoC1 plasma 
levels were detected between the samples from persons with incident diabetes and persons 
not developing diabetes neither in total (Fig 6.7B) nor in apoB-depleted plasma, the latter of 
which was used as a surrogate for HDL (Fig 6.7C). 
A potentially important limitation of both, the cross-sectional and the longitudinal study, is 
the fact that we investigated CAD patients. In a recent proteomics study, my lab found a 
decreased apoC1 content in HDL of patients with type 2 DM and/or CAD compared to HDL 
from healthy control subjects 168. However, the apoC1 content did not differ between CAD 
patients with or without type 2 DM. In addition, other studies found decreased apoC1 levels 
in HDL of CAD patients and a correlation between the risk for CAD with low apoC1  
levels 169–171. Thus, the analysis of CAD patients may have been inappropriate to unravel any 
association of the glycemic state of the plasma donors with the apoC1 content and the anti-
apoptotic activity of HDL.   
At first sight paradoxically, HDL from subjects with higher TG or lower HDL-C plasma levels 
protected INS-1E cells better against IL-1-induced apoptosis (Fig 6.6D+E). We found no 
significant correlation between TG and the apoC1 content of the respective HDL in the cross-
sectional study (r=0.2855, p=0.1333, Tab 6.2) but a significant positive correlation between TG 
levels and apoC1 in both total and apoB-depleted plasma in the longitudinal study (r=0.5117, 
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p<0.0001; r=0.6207, p<0.0001, Tab 6.3). A correlation of plasma apoC1 and TG concentration 
was described in a study of men suffering from metabolic syndrome 172. The authors explained 
their findings with the fact that apoC1 inhibits the lipoprotein lipase and stabilizes VLDL. 
Moreover, it has been described that apoC1 increases VLDL levels as it interferes with the 
removal of TG-rich lipoproteins by LDL receptor, Low density lipoprotein receptor-related 
protein 1 (LRP1) and VLDL receptor 80,164. Thus, the higher TG levels and the better anti-
apoptotic protection of the respective HDL could both be a consequence of higher apoC1 
levels. Otherwise, apoC1 inhibits CETP and thereby stabilizes HDL particles. This inhibitory 
effect was found to be attenuated by glycation of apoC1 that occurs typically in type 1, or type 
2 DM 173. Since the majority of the study subjects had an impaired glucose tolerance 
(metabolic syndrome or type 2 DM), such an impaired CETP inhibition by glycated apoC1 
seems plausible in our cohort. Relatively high CETP action combined with high VLDL levels will 
load HDL with TG, increase HDL clearance and thus lower HDL-C levels. As for our experiments 
HDL was dosed according to its protein concentration and as HDL-C is not necessarily a good 
predictor of HDL quality 79, the inverse correlation of HDL-C and anti-apoptotic potential is not 
contradictory.  
In summary, the significant correlation between the apoC1 content and the anti-apoptotic 
potential of the HDL samples in the cross-sectional study supports an anti-apoptotic role of 
apoC1 in humans. However, our data from the longitudinal study is insufficient to show 
whether apoC1 reduces the risk to develop type 2 DM.  
 
7.1.4. Problems with Apoptosis Induction and Prevention 
Additional experiments had been planned for the analysis of the anti-apoptotic effect of 
apoC1. However, in the beginning of 2013 two major problems made it impossible to 
continue. Apoptosis induction in INS-1E cells with IL-1 worked robustly and was prevented 
by 50% and more by HDL (50 g/ml) or apoC1 (5 g/ml) for more than three years in our hands 
(as in Fig. 7.1A). However, these effects were getting considerably weaker and unstable in 
spring 2013: First, we had problems to prevent apoptosis by more than 30% (as in Fig. 7.1B). 
The replacement of different cell culture components (plates, media, HDL and apoC1, using 
cells frozen down at a lower passage number, replacing the INS-1E cells with isolates obtained 
from C. Wollheim and P. Maechler in Geneva (who originally isolated the INS-1E clone from 
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INS-1 cells 151), did not solve these problems. Instead, we suddenly faced the loss of the IL-1 
effect by the end of April 2013 (as in Fig. 7.1C). Whereas the apoptosis induced by 24 hours of 
IL-1-treatment had been usually in the range of fourfold to even 20-fold, the effect of the 
same treatment was then often below twofold induction of apoptosis. The use of other IL-1 
preparations did not restore the effect. Neither could we solve the problem by the use of 
alternative assays for the recording of apoptosis, for example by caspase-3 activity, or annexin 
V / propidium iodide staining in flow cytometry (data not shown). A summary of all 
experiments done between February and August 2013 illustrates the inconsistency of the 
experiments (Fig. 7.1D).   
Despite extensive efforts, we could not identify the culprit. Possibly, we had recorded effects 
on a small number of cells with our apoptosis assay that measured the fold induction of 







Figure 7.1: Problems with apoptosis prevention and induction. 
A: Experiment of 19th of October 2012 (typical experiment): INS-1E cells were cultured for 40 hours in 
the presence of HDL or apoC1 at the indicated concentrations. During the last 24 hours, IL-1 (10 
ng/ml) was added for the stimulation of apoptosis except in the not treated control (Ctrl) condition. 
B: Experiment of 28th of February 2013: INS-1E cells were treated as described in A 
C: Experiment of 17th of May 2013: INS-1E cells were treated as described in A, IL-1 from our usual 
supplier (Pep for Peprotech) was compared to IL-1from R&D (each at 10 ng/ml).  
D: Overview of all experiments done between February and August 2013 







7.2. Apoptotic Signaling Analysis 
Several gene expression studies have been undertaken to investigate the effect of IL-1 in 
pancreatic -cells – mostly in combination with interferon  (IFN) or other cytokines 44,174,175. 
Also on the protein level, a previous study identified differentially regulated proteins in 
response to IL-1 treatment in pancreatic islets 176. The modulation of apoptotic pathways by 
HDL has been explored only by one study of Pétremand and collegues in -TC3 cells subjected 
to serum deprivation and incubation with or without 1mM HDL-C 109. Thus, we performed a 
genome-wide expression analysis at the Functional Genomics Center Zürich (FGCZ) and 
several follow-up experiments to elucidate the signaling cascades by which HDL inhibited IL-
1-induced apoptosis of pancreatic -cells in INS-1E cells.  
 
7.2.1. Effects of Interleukin-1and HDL on Gene Transcription 
The cluster analysis revealed that the effect of IL-1 on transcription outraged the 
consequences of HDL treatment on gene expression by far (Fig 6.8). The changes in gene 
expression in response to the respective treatments were summarized in functional 
annotation clusters. After 12 h and 24 h IL-1 stimulation, these annotation clusters indicated 
massive changes in immune and inflammatory responses, cell death, regulation of cytokine 
production, cell cycle regulation, and protein biosynthesis (Tab 6.4). The results of our gene 
array analysis were thus similar to the findings of the Eizirik group who had identified 
differentially regulated genes and pathways in response to cytokine treatment 44,174. In 
contrast to our data however, Eizirik and colleagues stated repeatedly that IL-1 does not 
trigger -cell apoptosis on its own 44,174,177,178. Larsen and colleagues described differentially 
expressed proteins in response to IL-1-exposure in primary rat islets 176. After separation with 
high-resolution 2D-gel electrophoresis, proteins belonging to energy transduction; the 
glycolytic pathway; protein synthesis, chaperones, and protein folding; and signal 
transduction, regulation, differentiation, and apoptosis were identified with mass 
spectrometry.  
Unfortunately, genes differentially regulated by IL-1 and HDL had high false discovery rates 
in our study (> 0.5101). The subsequent search for annotation clusters of differentially 
regulated genes yielded considerably lower enrichment scores (Tab 6.5). These clusters 
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included the regulation of transcription factors (NF-B among others), the endoplasmic 
reticulum stress response, protein biosynthesis, the induction of apoptosis, lipid biosynthetic 
processes, glucose metabolism, the response to hormone and cytokine stimuli, and cellular 
development. Given the relatively low enrichment scores and high false discovery rates, this 
data was interpreted with caution. A possible explanation for the poor outcome in the search 
for differentially regulated genes is the timing of the experiments. Since RNA transcription 
adapts within hours to certain stimuli, our collection times after 12 h and 24 h IL-1 incubation 
might have missed essential changes in expression which could have increased the survival of 
the HDL treated cells.  
Thus, ten candidate genes of the apoptotic pathway that had been slightly differentially 
regulated by IL-1 and HDL in the gene array were re-analyzed by quantitative real-time PCR 
(qPCR) at additional time points, i.e. after 3 to 24 h IL-1 incubation in the presence or absence 
of HDL. The selected genes were located in the ER stress pathway, in the intrinsic or extrinsic 
apoptotic pathway (Fig 6.10). Although considerable changes in expression over time were 
detected for some genes, the differences between IL-1treated cells with and without HDL 
on the gene expression level were minor compared to the pronounced effect of IL-1-versus 
not treated cells (Tab 6.6). These results corroborated a massive effect of IL-1stimulation on 
gene expression in INS-1E cells. More importantly, they affirmed our previous notion that the 
primary protective action of HDL against IL-1-induced apoptosis might not be found at the 
transcription level. We therefore sought to investigate the NF-B signaling and the ER stress 
response with independent experiments.  
 
7.2.2. Investigation of NF-B  
The transcription factor NF-B – among other functions – is important for the expression of 
genes related to cell survival and apoptosis 179. NF-B is involved in the progression of several 
metabolic diseases 180. The inhibition of NF-B by salicylates resulted in the amelioration of 
glucose homeostasis and insulin resistance in a mouse model. Overexpression of IB, an 
inhibitor of NF-B, protected pancreatic islet cells from IL-1-induced cell death 181. In 
pancreatic -cells, NF-B translocation (i.e. activation) in response to short-term  
IL-1exposure had protective effects whilst it induced apoptosis when IL-1 stimulation 
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persisted 182. Moreover, an NF-B blockade resulted in -cell protection against diabetogenic 
agents in vitro and in vivo 183. 
As expected, we observed a reversible translocation of NF-B (subunit p65) into the nucleus 
in response to IL-1 treatment in INS-1E cells (Fig 6.11). Unfortunately, the presence of HDL 
did not modify the NF-B translocation under the tested conditions (i.e. 0, 5, 15 and  
60 minutes, and 5 and 24 hours of IL-1 incubation). Additional time points might have 
revealed a different translocation pattern in cells treated with and without HDL. However, 
HDL was  neither found to alter the distribution of NF-B in another -cell line 109. Thus, there 
is good reason to assume that HDL interferes with apopotosis independently of the NF-B 
pathway. We therefore focused on the investigation of other ER stress related pathways.  
 
7.2.3.  Investigation of ER Stress  
Several genes of the ER stress response pathway were found to be differentially regulated by 
IL-1 and HDL in our gene array analysis. Moreover, it was described beforehand that IL-1 
(partly in combination with other cytokines) induces ER stress in pancreatic -cells 38,44,46,184. 
Christian Widmann’s group previously demonstrated that HDL resolves ER stress and ER stress 
related apoptosis in Min6 cells and primary beta cells 109,111. Thus, in a collaboration with 
Christian Widmann’s group we investigated whether HDL and especially its component apoC1 
reduced ER stress and ER stress-induced apoptosis in Min6 cells. Whereas the activation of 
PERK and subsequent apoptosis by the ER stressor thapsigargin (ThG) were partially prevented 
by HDL and the higher dose of apoC1, the ThG-stimulated expression of CHOP was clearly 
reduced by HDL but not apoC1 (Fig 6.12A-C). Experiments in INS-1E cells confirmed a 
protective role of HDL against ThG-induced apoptosis for -cells. However, no protective 
effect of apoC1 was found in these experiments (Fig 6.12D). Albeit IL-1 stimulation triggers 
ER stress, we conclude that the mechanism by which ThG induces ER stress and subsequent 
apoptosis differs from the IL-1-induced apoptosis pathway. Any protective effect of apoC1 
seems to be exerted on a pathway that is not modified by ThG. This is similar to an observation 
of the Widmann group, who described earlier that HDL protected -cells against different 
stressors by diverse means 109. Meanwhile, my laboratory found that HDL prevents ThG-
induced apoptosis of INS-1E cells by a mechanism which involves the mobilization of sterols, 
and which requires exclusively apoA1/phospholipid particles 185. This finding further 
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underscores the assumption that HDL elicits different anti-apoptotic mechanisms by different 
pathways and components. Specifically, cytokine- and ER-stress-induced apoptosis of INS-1E 
cells are inhibited by HDL through different mechanisms with different structural 
requirements.  
 
7.2.4. Problems with Apoptosis Induction and Prevention 
The problems described in section 7.1.5 hampered the investigation in IL-1- and HDL-
modulated signaling pathways as well. In contrast to IL-1-induced apoptosis, ThG-induced 
apoptosis was continuously and robustly working: apoptosis was detected with two additional 
assays (annexin V / propidium iodide (PI) staining and caspase 3 activation, Fig 6.13A+B). Since 
apoC1 did not prevent ThG-induced apoptosis however, we could not use this model to 





7.3. Clinical Studies on the Impact of Diabetes on HDL Functionality 
Since our analyses on the anti-apoptotic effect of apoC1 in INS-1E cells could not proceed, we 
investigated the components of HDL that might interfere with ThG-induced apoptosis of 
pancreatic -cells. By case-control studies, we sought to investigate the impact of type 1 and 
type 2 DM on the ability of HDL to protect INS-1E cells from ThG-induced apoptosis. In 
addition, the potential of HDL to stimulate cholesterol efflux from macrophages, as well as to 
regulate NO production, adhesion molecule expression and starvation-induced apoptosis in 
endothelial cells were investigated. These comprehensive studies aimed to check whether 
type 1 and type 2 DM share dysfunctions, and whether the different functionalities of HDL 
correlate with each other. The cholesterol homeostasis of -cell membranes is known to play 
an important role in the regulation of insulin secretion 113,114,116,120. Moreover, recent studies 
of my lab provided evidence that the protection of INS-1E cells by HDL from ThG-induced 
apoptosis involves the mobilization of sterols 185.  
To rule out any interference of CAD (see 7.1.3) we compared the protective effects of HDL 
from patients with or without CAD, normal or impaired fasting glucose or type 2 DM. 
Unfortunately, no differences in ThG-induced apoptosis reduction were detected for these 
HDL samples (Fig 6.14B). Correlation analysis of the apoptosis reduction with the clinical 
parameters of the study subjects did not reveal any significant associations once we adjusted 
for multiple testing (Tab 6.9). The HDL samples from the different groups differed neither by 
their abilities to protect human aortic endothelial cells (HAECs) from starvation induced 
apoptosis nor to elicit NO production in bovine aortic endothelial cells (data not shown). At 
first sight, the negative findings suggest that the anti-apoptotic effect of HDL towards 
pancreatic -cells is robust and not affected by disease. However, the endothelial functions of 
HDL were found to be adversely affected by diabetes and CAD by several groups 77,95,186–189. 
The negative findings also question the arguments of our discussion on the negative findings 
in the case-control study on IL-1-induced apoptosis (see 6.1.7 and 7.1.3), namely that the 
presence of CAD hides any differences between diabetic and non-diabetic subjects. However, 
the control subjects (without established coronary artery disease and with normal fasting 
glucose) were neither healthy. Most of them received treatment for hypertension (beta 
blockers, ACE inhibitors), aspirin or statins (Tab 5). In conjunction with the relatively high 
analytical variation of the bioassays and the rather small sample number, our study may have 
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not been powered enough to find any significant differences between the control subjects and 
the patient groups. In fact, previous studies from our lab compared CAD patients and very 
healthy blood donors, for example towards the endothelial functionality of HDL 77,95,189. In a 
recent very comprehensive systems biology study, my lab compared HDL of 50 healthy 
volunteers with HDL of 100 patients with either diabetes, CAD or both 168. In this study, the 
ability of HDL to protect INS-1E cells from ThG-induced apoptosis was impaired in CAD patients 
whereas the ability of the HDL to prevent starvation-induced apoptosis of HAECs was impaired 
in diabetic patients compared to HDL from healthy subjects. In line with this difference, the 
two activities were found to have different structural determinants.  
Type 2 DM patients often suffer from comorbidities such as obesity, hypertension, macro- and 
microvascular diseases, chronic kidney disease, depression, and/or cognitive decline 24,190. It 
has been demonstrated before that several diseases – including type 2 DM – change the 
composition and functionality of HDL 67,77,93–95,191. However, because many comorbidities are 
present already at the time point of diagnosis and because many of them cause structural and 
functional changes of HDL, it is difficult to resolve structure-function-disease relationships of 
HDL in type 2 DM.  It was therefore particularly interesting to investigate the protective effects 
of HDL from adolescent type 1 DM patients towards -cell apoptosis, because comorbidities 
presumably had not evolved at this early stage of disease. Thus, any changes in anti-apoptotic 
activity of HDL from adolescents with type 1 DM could be assigned to type 1 DM-related HDL 
remodeling.  In fact, two studies found evidence for disturbed HDL function in type 1 diabetes, 
i.e. a decreased HDL-apoA1 exchange rate and an impaired cholesterol efflux capacity, 
respectively 192,193.  
HDL isolated from diabetic adolescents had slightly but not significantly less anti-apoptotic 
potential on INS-1E cells compared to HDL isolated from age-matched, healthy adolescents 
(p=0.3535, Fig 6.14A). Cholesterol efflux experiments from J774 macrophages with and 
without previous cAMP-stimulation of the ABCA1 receptor expression revealed a similar 
picture. In both conditions, HDL from adolescents with type 1 DM induced slightly less 
cholesterol efflux (Fig 6.15A+B). The differences were not significant though (p=0.0971 
without cAMP stimulation, p=0.5040 with cAMP stimulation).  
As expected, cholesterol efflux from macrophages with prior cAMP stimulation correlated 
with cholesterol efflux without prior cAMP stimulation (Tab 6.8). Otherwise, correlation 
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analysis of the functional tests with the clinical parameters of the study subjects did not reveal 
any significant associations after adjustment for multiple testing (Tab 6.7).   
Further experiments of coworkers with the same HDL samples in endothelial cells likewise 
yielded little and mostly insignificant differences between patients with type 1 DM and 
healthy controls: HDL from adolescents with type 1 DM was a less potent stimulator of NO 
release from bovine aortic endothelial cells than HDL from the age-matched healthy control 
subjects (76.60% ± 6.785% vs. 100.5% ± 8.238%, p=0.0409). HDL from the type 1 diabetic 
donors was but slightly less active than HDL from control subjects to protect human aortic 
endothelial cells against starvation-induced apoptosis (81.55% ± 4.903% vs. 88.29% ± 5.866%, 
p=0.4108) or stimulated VCAM-1 expression (91.91% ± 3.278% vs. 87.09% ± 3.015%, 
p=0.3063).  
These results did not motivate further experiments to investigate the quality and composition 
of the tested HDL samples. A higher sample number could have possibly unraveled significant 
differences between HDL of adolescents with or without type 1 DM. Thus, we cannot assess 
whether the small deteriorations in the function of our HDL samples from adolescents with 
type 1 DM mirror the early and persistent decreases in HDL function of type 1 diabetic 





7.4. Conclusion  
The first aim of this PhD project was to identify HDL components with anti-apoptotic effects 
on pancreatic -cells. This issue was addressed in INS-1E cells, a rat pancreatic -cell line, with 
interleukin-1 (IL-1)-induced apoptosis. Whereas the previously described anti-apoptotic 
components apoA1 and S1P 88 did not reduce apoptosis significantly in our -cell model, apoC1 
was found protect INS-1E cells against IL-1-induced apoptosis (see section 7.1.1.). With 
apoC1-deficient murine HDL, we sought to estimate the relevance of apoC1 within HDL for its 
anti-apoptotic effect (see section 7.1.2.). However, the differences between the effects of 
murine and human HDL on -cells overrode the magnitude of apoC1’s anti-apoptotic effects. 
Since apoC1 levels were described to be lower in subjects with metabolic diseases 93, we 
decided to investigate this question by testing the effect of HDL from different patient groups 
(see 7.1.3.). The glycemic state of the study subjects did not associate with the anti-apoptotic 
activity of the tested HDL samples on INS-1E cells, but we observed a positive correlation 
between the apoC1 content and the ability of the respective HDL to reduce apoptosis in all of 
the study samples. However, we did not find any association of apoC1 plasma levels with the 
presence or incidence of diabetes, possibly because we investigated CAD patients who are 
also known to have lower apoC1 levels in HDL 169–171 (see 7.1.4.). 
To identify receptors and signaling pathways, by which HDL and apoC1 interfere with IL-1-
induced apoptosis, we performed a genome-wide expression analysis. In contrast to the 
massive gene expression changes in response to IL-1 treatment, the presence or absence of 
HDL induced but minor differential gene regulation (see 7.2.1.). These differentially regulated 
pathways included the transcription factor NF-B and the response to ER stress. The validation 
experiments confirmed that IL-1 promotes the NF-B translocation from the cytosol into the 
nucleus but did not provide any evidence that HDL interferes with this (see 7.2.2.). 
Unfortunately, the collapse of our apoptosis model hampered further experiments to 
characterize any mechanism by which apoC1-may interfere with IL-1-induced apoptois of 
INS-1E cells (see 7.1.5.).  
We therefore started the investigation of another model of -cell apoptosis, namely ER-stress 
related apoptosis induced by thapsigargin 109,111. We confirmed the protective effect of HDL 
in INS-1E cells. However, apoC1 did not mimic the protective effect of HDL against 
thapsigargin-induced apoptosis (see 7.2.3.). We thus assume that the protective effect of 
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apoC1 against IL-1-induced apoptosis lies in a branch of the apoptotic pathway that is not 
modified by the ER stressor thapsigargin. With HDL samples from different patient groups, we 
sought to identify protective HDL components against ER stress-related apoptosis induced by 
ThG. Regrettably, neither type 2 DM nor type 1 DM was associated with any difference in the 
ability of HDL to protect INS-1E cells from ThG-induced apoptosis (see 7.3). Because of the 
high variation of the bioassay and because of confounding, we cannot rule out that our studies 
had too little statistical power to unravel any significant difference between the groups.  
We found some evidence that apoC1 contributes to the ability of HDL to protect pancreatic -
cells from IL-1-induced apoptosis but not to the ability of HDL to inhibit ER-stress. Otherwise, 
recent studies of my lab found that the protection of INS-1E cells by HDL from ThG-induced 
apoptosis involves the mobilization of sterols 185. Moreover, coworkers from my lab 
discovered that HDL from CAD patients was less able to protect INS-1E cells from ThG-induced 
apoptosis whereas the ability of the HDL to prevent starvation-induced apoptosis of HAECs 
was impaired in diabetic patients compared to HDL from healthy subjects 168. Interestingly, 
the two features were found to have different structural determinants.  
In conclusion, different structural determinants and mechanisms seem to account for the 
ability of HDL to protect INS-1E cells from IL-1- and ThG-/ER-stress-induced apoptosis. 
Unfortunately, our in vitro findings on the anti-apoptotic activities of HDL and apoC1 could 
not be translated into bioassays and biomarkers that help to identify patients with increased 
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